## RSV and Rhinovirus asymptomatic upper airway infection increases pneumococcal carriage acquisition rates and density in adults whereas nasal inflammation is associated with bacterial shedding.

Elena Mitsi<sup>21</sup>, Elissavet Nikolaou<sup>21</sup>, Andre Goncalves<sup>21</sup>, Annie Blizard<sup>2</sup>, Helen Hill<sup>-</sup>, Madlen Farrar<sup>2</sup><br>Angela Hyder-Wright<sup>2</sup>, Ashleigh Howard<sup>2</sup>, Filora Elterish<sup>1</sup>, Carla Solorzano<sup>1,2</sup>, Ryan Robinson<sup>2</sup>, Jesu<br>R ,<br>s<br>1. Angela Hyder-Wright", Ashleigh Howard", Filora Elterish", Carla Solorzano<sup>2</sup>", Ryan Robinson", Jesus<br>Reine<sup>1,2</sup>, Andrea M. Collins<sup>2</sup>, Stephen B. Gordon<sup>2,4</sup>, Jeffrey N. Weiser<sup>5</sup>, Debby Bogaert<sup>6,7</sup>, Daniela M.<br>Ferreira<sup>1</sup> Reine\*\*\*, Andrea M. Collins\*, Stephen B. Gordon\*\*\*, Jeffrey N. Weiser\*<br>Ferreira<sup>1,2</sup>.<br>Authors and affiliations<br><sup>1</sup> Oxford Vaccine Group, Department of Paediatrics, University of Ox<br><sup>2</sup> Clinical Sciences Department. Liverpo , Debby Bogaert<sup>o,,</sup>, Daniela M.<br>ford, Oxford, UK<br>e. Liverpool. UK

t,

Ferreira<sup>4,2</sup><br>Authors an<br><sup>1</sup> Oxford Va<br><sup>2</sup> Clinical Sc <sup>1</sup> Oxford Vaccine Group,<br><sup>2</sup> Clinical Sciences Depar<br><sup>3</sup> Murdoch Children's Re<br><sup>4</sup> Malawi Liverpool Well<sup>,</sup><br><sup>5</sup>Department of Microbi <sup>2</sup> Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK

Ĭ

Murdoch Children's Research Institute, *Melbourne*, Australia<br>Malawi Liverpool Wellcome-Trust Programme, Blantyre, Mala<br>Department of Microbiology, New York University School of N<br>Centre for Inflammation Research, Universi <sup>4</sup> Malawi Liverpool Wellcome-Trust Programme, Blantyre, Malawi

Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK<br>Murdoch Children's Research Institute, Melbourne, Australia<br>Malawi Liverpool Wellcome-Trust Programme, Blantyre, Malawi<br>Department of Micro Clinical Sciences Department, Liverpool Children's Research Institute, *Melbourne*, Australia<br>
Malawi Liverpool Wellcome-Trust Programme, Blantyre, Malawi<br>
Department of Microbiology, New York University School of Medicine Department of Microbiology, New York University School of Medi<br>Centre for Inflammation Research, University of Edinburgh, Edinb<br>Department of Paediatric Immunology and Infectious Diseases, U <sup>5</sup>Department of Microbiology, New York University School of Medicine, New York, USA

Ĭ

Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdor<br>Department of Paediatric Immunology and Infectious Diseases, Utrecht, The Netherlar<br>Corresponding authors: <u>daniela.ferreira@paediatrics.</u> Cepartment of Paediatric Immunology and Infectious Diseases, Utrecht, The Netherland<br>Corresponding authors: <u>daniela.ferreira@paediatrics.ox.ac.uk, elena.mitsi@paediatrics.o</u>  $<sup>7</sup>$ Department of Paediatric Immunology and Infectious Diseases, Utrecht, The Netherlands</sup>

 $D$  . The matrix of  $D$  and  $D$  and  $D$  and  $D$  are infected infection,  $D$  and  $D$ ,  $D$  and  $\overline{a}$  $\overline{a}$ Corresponding authors: daniela.ferreira.ferreira.ferreira.ferreira.<br>.<br>.

 $\overline{a}$  $\frac{1}{2}$  $\frac{1}{2}$ l<br>İ l<br>i Key words: Register of the U.S. Archives inflammation<br>TE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical praction.<br>TE: This preprint reports new resea

## **ABSTRACT**

r<br>F<br>F Nasopharyngeal preumococcal spread and transmission. Most epidemiological studies report the impact of co-infection with respiratory viruses upon disease rates and outcome, but their effect on pneumococcal carriage acquisi primary reservoir of bacterial spread and manufaterial model spreading comment open transmitted in the spiral model<br>impact of co-infection with respiratory viruses upon disease rates and outcome, but their effect on<br>pneumo impact of co-inference interesting in the co-principal specified and outcome, then and outcomes pheumococcal carriage acquisition and bacterial load is scarcely described. Here, we used controlled<br>human infection with pneu production antingo acquisition and bacterial vention carrier, accuration (i) at an expectibility<br>to pneumococcal colonisation and bacterial density. A total of 581 healthy adults were screened for<br>presence of upper respira human infection and bacterial density. A total of 581 healthy adults were screened for<br>presence of upper respiratory tract viral infection before intranasal pneumococcal challenge. We<br>showed that RSV and Rhinovirus asympto presence of upper respiratory tract viral infection before intranasal pneumococcal challenge. We<br>showed that RSV and Rhinovirus asymptomatic infection conferred a substantial increase in carriage<br>rates (88% and 66% of colo presence of the Karl Showed that RSV and Rhinovirus asymptomatic infection conferred a substantial increase in carriage<br>rates (88% and 66% of colonised individuals in Rhinovirus and RSV infected groups, respectively, vs<br>49 showed that RSV and 66% of colonised individuals in Rhinovirus and RSV infected groups, respectively, vs<br>49% in the virus negative group). The risk ratio of pneumococcal colonization in RSV infected group<br>was 5.3 (95% CI: 49% in the virus negative group). The risk ratio of pneumococcal colonization in RSV infected group<br>was 5.3 (95% CI: 0.90 – 30.61, p = 0.034) and 2.03 (95% CI: 1.09-3.80, p= 0.035) in rhinovirus infected<br>group. Pneumococc was 5.3 (95% CI: 0.90 – 30.61,  $p = 0.034$ ) and 2.03 (95% CI: 1.09-3.80,  $p = 0.035$ ) in rhinovirus infected<br>group. Pneumococcal density was overall greater in virus positive subjects, although RSV infection<br>alone had a maj matrix (1956) CI: 0.90 (1956) CI: 0.90 (1956) Space, process process process process although RSV infection alone had a major impact on pneumococcal density up to 9 days post challenge, with a substantial 2-<br>log increase alone had a major impact on pneumococcal density up to 9 days post challenge, with a substantial 2-<br>log increase at D2 compared to virus negative group (median, SEM: 3.76 ± 0.65 vs 1.79 ± 0.09) (p=<br>0.02). We also studied r alone had a major intervals and kinetics of bacterial shedding through the nose and oral route in a<br>aubset of challenged individuals. Nasal bacterial shedding through the nose and oral route in a<br>subset of challenged indiv door the set of challenged individuals. Nasal bacterial shedding through the nose and oral route in a subset of challenged individuals. Nasal bacterial shedding was twice more frequent than coughinduced shedding (64% vs 32 subset of challenged individuals. Nasal bacterial shedding was twice more frequent than cough-<br>induced shedding (64% vs 32%, respectively). High levels of bacterial colonisation density and nasal<br>inflammation was strongly

with high density and have local inflammation, two key characteristics of pneumococcal colonisation<br>in paediatrics and/or viral co-infection. Hence, vaccines targeting these respiratory pathogens have inflammation was strongly correlated with increased odds of nasal shedding, as opposed to cough-<br>shedding.<br>Healthy adults can act as reservoir of transmission for pneumococcus, particularly when colonised<br>with high density inflammation was strongly correlated with increased odds of nasal shedding, as opposed to cough-ی<br>Healthy ac<br>with high<br>in paediat<br>the dual p<br>target patl Healthy adults can act as reservoir of transmission in parameters (parameters), particularly with high density and have local inflammation, two key characteristics of pneumococcal colonisation in paediatrics and/or viral c in paediatrics and/or viral co-infection. Hence, vaccines targeting these respiratory pathogens have<br>the dual potential of reducing transmission and disease burden due to their indirect benefit to off<br>target pathogens. in parameter and, or what co-infection. Hence, vacance, infection, parametering the dual potential of reducing transmission and disease burden due to their indirect benefit to off target pathogens. target pathogens.<br>
The dual potential of reducing transmission and disease burden due to the indirect benefit to off the state b target pathogens.

2 Streptococcus pr<br>
2 Streptococcus pr<br>
3 respiratory tract<br>
4 prevalence in yo<br>
5 Although colonis<br>
6 and young chile 2 Streptococcus pheumoniae (the pheumococcus) is a leading opportunistic pathogen of the human<br>
2 respiratory tract. Nasopharyngeal pneumococcal colonisation is a common event, with 40-90%<br>
4 prevalence in young children ( 3 prevalence in young children (<5 years old) and 10-20% in adults in epidemiological studies [1-4].<br>
3 Although colonisation of the nasopharynx is generally considered asymptomatic (the carrier state),<br>
3 and young childr Although colonisation of the nasopharynx is generally considered asymptomatic (the carrier state),<br>and young children experience multiple colonisation episodes, mostly without incident, under<br>certain circumstances pneumoco 5 and young children experience multiple colonisation episodes, mostly without incident, under<br>5 certain circumstances pneumococci can invade sites and spread within the host, resulting in disease<br>5 development[5-7]. This Frain circumstances pneumococci can invade sites and spread within the host, resulting in disease<br>
development[5-7]. This paradox suggests that other factors beyond nasopharyngeal carriage play an<br>
important role in the pa

2 development [5-7]. This paradox suggests that other factors beyond nasopharyngeal carriage play an<br>
19 important role in the pathogenesis of pneumococcal disease [8, 9].<br>
2 Viral infections, mainly respiratory syncytial 8 important role in the pathogenesis of pneumococcal disease [8, 9].<br>
8 Viral infections, mainly respiratory syncytial virus (RSV) and influenza, seem to increase substantially<br>
1 the risk of secondary pneumococcal infecti 9 Viral infections, mainly respiratory syncytial virus (RSV) and influen<br>1 the risk of secondary pneumococcal infection, including invasive<br>2 11]. Epidemiological, clinical and experimental evidence suggest that<br>3 virulenc 11 the risk of secondary pneumococcal infection, including invasive pneumococcal disease (IPD) [10,<br>12 11]. Epidemiological, clinical and experimental evidence suggest that these viruses increase bacterial<br>13 virulence and 11 11. Epidemiological, clinical and experimental evidence suggest that these viruses increase bacterial<br>13 virulence and worsening disease outcome [12, 13], implying that non-invasive pneumococcal<br>14 serotypes possibly re 13 virulence and worsening disease outcome [12, 13], implying that non-invasive pneumococcal<br>14 serotypes possibly require enhancement by respiratory viruses to cause secondary bacterial<br>15 infection.<br>16 Colonisation is al

14 serotypes possibly require enhancement by respiratory viruses to cause secondary bacterial<br>15 infection.<br>16 Colonisation is also the primary source and reservoir of pneumococcal transmission [6]. It is<br>17 postulated tha 15 infection.<br>16 Colonisation is also the primary source and reservoir of pneumococcal transmission [6]. It is<br>17 postulated that a colonised person can shed bacteria via nasal secretion and mucosalivary fluid in<br>18 the fo 16 Colonisati<br>17 postulated<br>18 the form<br>19 especially<br>20 upper resp 17 postulated that a colonised person can shed bacteria via nasal secretion and mucosalivary fluid in<br>18 the form of droplets [14]. Colonisation and transmission are most common among young children,<br>19 especially in crowd 18 the form of droplets [14]. Colonisation and transmission are most common among young children,<br>19 especially in crowded settings, such as day care centres [15], or in association with episodes of viral<br>17 upper respirat 19 especially in crowded settings, such as day care centres [15], or in association with episodes of viral<br>
18 upper respiratory tract infection [16-18]. In animal models, higher density of colonising bacteria and<br>
18 incr 19 especially in contract infection [16-18]. In animal models, higher density of colonising bacteria and<br>19 increased nasal secretions triggered by influenza, leads to increased bacterial shedding [19]. In<br>19 humans, influ upper respiratory tract infection [16-18]. In animal models, higher density of colonising bacteria and<br>21 increased nasal secretions triggered by influenza, leads to increased bacterial shedding [19]. In<br>22 humans, influen 22 humans, influenza infection induced by Live attenuated influenza vaccine can trigger acute nasal<br>23 inflammation [20] and lead to higher density of colonising pneumococci [20, 21]. In children, viral<br>24 rhinitis has als

23 inflammation [20] and lead to higher density of colonising pneumococci [20, 21]. In children, viral<br>24 rhinitis has also been associated with elevated pneumococcal colonising density in children [22].<br>25 Here we studied 23 Inflammation [20] and lead to higher density of colonising presentation [20] and higher density in children [22].<br>25 Here we studied the relationship between certain respiratory viruses and predisposition to<br>26 pneumoco 25 Here we studied the relationship between certain respiratory viruses and predisposition<br>26 pneumococcal colonisation using a controlled human infection model with pneumococcus in ad<br>27 As the onset of colonisation is kn 26 12 12 pneumococcal colonisation using a controlled human infection model with pneumococcus in adults.<br>27 As the onset of colonisation is known, it ascertains pathogen order and causality on bacterial density<br>28 11 and h

27 As the onset of colonisation is known, it ascertains pathogen order and causality on bacterial density<br>28 and host responses.<br>29 In addition, we described the kinetics of bacterial shedding during early and later stages 28 and host responses.<br>29 In addition, we described the kinetics of bacterial shedding during early and later stages of<br>29 In addition and provided first evidence that adults can also act as reservoir of bacterial spread<br>2 29 In addition, we deed<br>29 In addition, we deed<br>30 colonisation and provided:<br>31 While they are colonies. 29 In addition, we describe the kinetic of bacterial shedding during early and later stages of<br>30 colonisation and provided first evidence that adults can also act as reservoir of bacterial spread<br>31 METHODS<br>32 METHODS 31 while they are colonised with S. pneumoniae.<br>32 **METHODS** 31 while they are colonised with S. pheamoniae.

# 32 METHODS

33 Study design and sample concedion<br>34 A total of 581 healthy adults (approximately preumococcal challenge studies in<br>36 November 2011 and October 2019, and a previously described [23]. All st<br>38 Research Ethics Committee 35 B preumococcal challenge studies in the Liverpool School of Tropical Medicine, UK, between<br>36 November 2011 and October 2019, were challenged intranasally with live pneumococci serotype 6B,<br>37 as previously described [2 November 2011 and October 2019, were challenged intranasally with live pneumococci serotype 6B,<br>37 as previously described [23]. All studies were approved by North-West National Health Service<br>38 Research Ethics Committee 37 as previously described [23]. All studies were approved by North-West National Health Service<br>38 Research Ethics Committee and participants gave informed consent. All participants were non-<br>39 smoking adults who had no 38 Research Ethics Committee and participants gave informed consent. All participants were non-<br>39 Smoking adults who had no close contact with at-risk individuals, such as young children (under the<br>39 age of 5 years) and

43 time points post inoculation, whereas oropharyngeal swabs were collected only at baseline. For a 39 smoking adults who had not contribute with at risk individuals). The median age of the subjects<br>39 and 321 (IQR:19-22) and 60% were female (351/581) (Table 1).<br>32 Nasal wash samples were collected before the intranasal was 21 (IQR:19-22) and 60% were female (351/581) (Table 1).<br>
42 Nasal wash samples were collected before the intranasal inoculation (screening visit) and at several<br>
43 time points post inoculation, whereas oropharyngeal Masal wash samples were collected before the intranasal inoction<br>43 time points post inoculation, whereas oropharyngeal swabs<br>44 subset of participants, nasal lining fluid (using Nasosorption<sup>TM</sup><br>45 curettes) were collect 43 time points post inoculation, whereas oropharyngeal swabs were collected only at baseline. For a<br>44 subset of participants, nasal lining fluid (using Nasosorption<sup>TM</sup> filters) and nasal cells (using Rhino-Pro<br>45 curett  $\mu$  subset of participants, nasal lining fluid (using Nasosorption<sup>TM</sup> filters) and nasal cells (using Rhino-Pro<br>as diverses) were collected at baseline and on days 2, 7 and 16 after challenge. Also, shedding samples,<br>su subset of participants, nasal lining fluid (using Nasosorption<sup>104</sup> filters) and nasal cells (using Rhino-Pro<br>
curettes) were collected at baseline and on days 2, 7 and 16 after challenge. Also, shedding samples,<br>
such as 14 curettes) were collected for a subset of participants on<br>45 cuch as cough plates and nose-to-hand (NtH) swabs were collected for a subset of participants on<br>47 days 2, 6, 16 and 22 after inoculation with pneumococcus se

days 2, 6, 16 and 22 after inoculation with pneumococcus serotype 6B.<br> **Pharmococcal colonisation and bacterial shedding**<br> **Pharmococcal detection was performed in NW samples by classic microbiology methods, as<br>
previously** 147 Days 2, 25 and 22 and 23 and 23 and 23 and 24 and 23 amples by classification with previously described 23, 24]. Participants in whom experimental pneumococcus semples at any v Friedmococcal detection was performed in NW<br>19 Pneumococcal detection was performed in NW<br>19 previously described[23, 24]. Participants in whom<br>19 samples at any visit post inoculation were defined as<br>19 To study bacterial

49 Previously described [23, 24]. Participants in whom experimental pneumococci were detected in NW<br>49 Samples at any visit post inoculation were defined as experimentally colonised.<br>49 To study bacterial shedding during e 51 samples at any visit post inoculation were defined as experimentally colonised.<br>52 To study bacterial shedding during experimental colonisation, we implemented sampling<br>53 methodologies, such as cough plate method and n 52 To study bacterial shedding during experimental colonisation, we im<br>53 methodologies, such as cough plate method and nose-to-hand swabbing,<br>54 evaluate longitudinally bacterial shedding from the oral and nasal<br>55 (Suppl 53 methodologies, such as cough plate method and nose-to-hand swabbing, which allowed us to<br>54 evaluate longitudinally bacterial shedding from the oral and nasal route, respectively<br>55 (Supplementary Fig.1). Post inoculati evaluate longitudinally bacterial shedding from the oral and nasal route, respectively<br>53 (Supplementary Fig.1). Post inoculation (at D2, D6, D14, D16 and D22) participants were asked to a)<br>56 cough twice on a blood agar p Statementally backet including the oral interesting from the oral and nationally respectively<br>55 (Supplementary Fig.1). Post inoculation (at D2, D6, D14, D16 and D22) participants were asked to a)<br>56 cough twice on a blood 55 (Supplementary Fig.1). Post increases the cough twice on a blood agar plate enriched with 4 µg/ml gentamicin (Sigma, UK) and b) rube their<br>57 nose using the anatomical snuff box of their hands. Then, the snuff box area 57 nose using the anatomical snuff box of their hands. Then, the snuff box area was swabbed using a<br>58 sterile cotton swab, following storage in STGG until sample processing. Both types of shedding<br>59 samples were collect 58 sterile cotton swab, following storage in STGG until sample processing. Both types of shedding<br>59 samples were collected before nasal wash or nasosorption samples collection to avoid artificial<br>50 induction and pneumoco 59 samples were collected before nasal wash or nasosorption samples collection to avoid artificial<br>50 induction and pneumococcal shedding was determined by classical microbiology methods in real<br>51 time. The cough plates 59 induction and pneumococcal shedding was determined by classical microbiology methods in real<br>51 time. The cough plates were incubated immediately at 37°C with 5% CO<sub>2</sub> for 24 hours. The NtH<br>52 swabs were streaked out o time. The cough plates were incubated immediately at  $37^{\circ}$ C with 5% CO<sub>2</sub> for 24 hours. The NtH<br>swabs were streaked out on a blood agar plate and an additional 20ul of the collected sample in<br>STGG was plated on a separ 52 swabs were streaked out on a blood agar plate and an additional 20ul of the collected sample in<br>63 STGG was plated on a separate plate enriched with gentamicin (Sigma, UK) and incubated overnight<br>64 at 37°C with 5% CO<sub></sub> STGG was plated on a separate plate enriched with gentamic Cigma, UK) and incubated overnight<br>at 37°C with 5% CO<sub>2</sub>. Following incubation, all the plates were inspected for presence of<br>at 37°C with 5% CO<sub>2</sub>. Following incu 64 at 37°C with 5% CO<sub>2</sub>. Following incubation, all the plates were inspected for presence of  $\mathcal{A}^{(1)}$  at 37 $\mathcal{A}^{(2)}$  with  $\mathcal{A}^{(3)}$  with  $\mathcal{A}^{(4)}$  and plates were inspected for presence of presence of  $\mathcal{A}^{(4)}$ 

65 agglutination. NtH samples were also tested for presence of pneumococcal DNA by a sequential<br>67 single-plex quantitative PCR (qPCR) using primers for *lytA* gene and cpr gene, specific for serotypes<br>68 6A/B, as previously So angle-plex quantitative PCR (qPCR) using primers for *lytA* gene and cpr gene, specific for serotypes<br>
68 6A/B, as previously published [25-27].<br> **DNA/RNA extraction and viral qPCR**<br>
70 Nucleic acids for viral qPCR were

68 6A/B, as previously published [25-27].<br>69 **DNA/RNA extraction and viral qPCR**<br>70 Nucleic acids for viral qPCR were extracted from one aliquot of 250⊠µL oropharyngeal swab and/or<br>71 150ul of a paired nasal wash sample c 68 6A/B, as previously published [25-27].<br> **69 DNA/RNA extraction and viral qPCR**<br>
70 Nucleic acids for viral qPCR were extra<br>
71 150ul of a paired nasal wash sample<br>
72 Purelink<sup>TM</sup> Viral RNA/DNA Mini Kit (Lif  $69$  DNA/RNA extraction and viral qPCR<br>
70 Nucleic acids for viral qPCR were ext<br>
71 150ul of a paired nasal wash samp<br>
72 Purelink<sup>TM</sup> Viral RNA/DNA Mini Kit (L<br>
73 the manufacturer's instructions. We<br>
74 probes and PCR 71 150ul of a paired nasal wash sample collected at baseline (5 days before inoculation) using the<br>
72 Purelink™ Viral RNA/DNA Mini Kit (Life Technologies Corporation, Carlsbad, CA, USA) according to<br>
73 the manufacturer The pair of a pair of the manufacturer's instructions. We tested for a broad panel of respiratory viruses using primers, probes an Purelink"" Viral RNA/DNA Mini Kit (Life Technologies Corporation, Carlsbad, CA, USA) according to<br>the manufacturer's instructions. We tested for a broad panel of respiratory viruses using primers,<br>probes and PCR assay cond probes and PCR assay conditions specific for adenoviruses, parainfluenza virus 1–4, human<br>
bocavirus, human coronavirus OC43, NL63 and 229E, respiratory syncytial virus (A and B), human<br>
metapneumovirus, human rhinoviruses 25 bocavirus, human coronavirus OC43, NL63 and 229E, respiratory syncytial virus (A and B), human<br>
76 metapneumovirus, human rhinoviruses, enteroviruses and human influenza virus A and B, as<br>
77 previously described[28].<br> metapneumovirus, human christianare occurs and the maintain properties of the state of the s

metapneumovirus, human rhinoviruses, enteroviruses and human influenza virus A and B, as<br>previously described[28].<br>**Cytokines analysis in nasal lining fluid**<br>Human nasal cytokines and chemokines were quantified in nasal wa 78 Cytokines analysis in nasa<br>79 Human nasal cytokines<br>80 customised cytokine stor<br>81 IFNβ1, IFNλ1, IL12, granzy 279 Human nasal cytokines and chemok<br>279 Human nasal cytokines and chemok<br>280 customised cytokine storm Olink Flex<br>281 IFNβ1, IFNλ1, IL12, granzyme A, IP-10,<br>282 Olink (Uppsala, Sweden) or a 30-Pl<br>283 Scientific), as prev 27 Human nasal cytokine storm Olink Flex 21 target panel (TNFa, IL1a, IL1b, IL6, IL8, IL2, IFNγ, IFNα2,<br>281 IFNβ1, IFNλ1, IL12, granzyme A, IP-10, MIG, MCP-1, MIP-1a, MIP-1b, GM-CSF, IL33, IL4, IL10) from<br>282 Olink (Uppsa 81 IFNβ1, IFNλ1, IL12, granzyme A, IP-10, MIG, MCP-1, MIP-1a, MIP-1b, GM-CSF, IL33, IL4, IL10) from<br>82 Olink (Uppsala, Sweden) or a 30-Plex Human Cytokine Magnetic Luminex Kit (Thermo Fisher<br>83 Scientific), as previously 82 Olink (Uppsala, Sweden) or a 30-Plex Human Cytokine Magnetic Luminex Kit (Thermo Fisher<br>83 Scientific), as previously described [20]. On the Olink platform the target protein bound to the<br>84 double oligonucleotide-labe Scientific), as previously described [20]. On the Olink platform the target protein bound to the<br>
84 double oligonucleotide-labelled antibody probe with high specificity, and then a microfluidic real-<br>
85 time PCR amplific 84 double oligonucleotide-labelled antibody probe with high specificity, and then a microfluidic real-<br>85 time PCR amplification of the oligonucleotide sequence was used to quantitatively detect the<br>86 resulting DNA sequen 84 double oligonucleotide-labelled antibody probe with high specificity, and then a microfluidic real-For any term amplitude in the oligonometric expenses the oligonometric quality control<br>87 time normalized, using internal and external controls. On the Luminex platform, NW samples were<br>88 analysed on a LX200 (Bio-Rad) wit and normalized, using internal and external controls. On the Luminex platform, NW samples were<br>analysed on a LX200 (Bio-Rad) with xPonent3.1 software (Luminex Corp) following the<br>manufacturer's instructions. All samples we and normalized, and particular and external controls. The Luminex platform, NY samples and standards were manufacturer's instructions. All samples were run in duplicate, and standards were run on all plates.<br>Calibration an manufacturer's instructions. All samples were run in duplicate, and standards were run on all plates.<br>
Calibration and verification beads were run prior to all runs. All cytokines' data (both Olink and<br>
Luminex panel) were Calibration and verification beads were run prior to all runs. All cytokines' data (both Olink and<br>
91 Luminex panel) were expressed in pg/ml.<br>
92 Nasal cell collection and immunophenotyping<br>
93 Nasal microbiopsies were co

Euminex panel) were expressed in pg/ml.<br>92 Nasal cell collection and immunophenotyping<br>93 Nasal microbiopsies were collecting by nasal curettage (Rhino-pro®, Arlington Scientific), as<br>94 described previously[29]. Two curet Masal cell collection and immunophenoty<br>92 Nasal microbiopsies were collecting by<br>94 described previously[29]. Two curette same inactivated FBS for immunophenotyping Nasal microbiopsies were collecting by nas<br>93 Nasal microbiopsies were collecting by nas<br>94 described previously[29]. Two curette samples<br>95 inactivated FBS for immunophenotyping and a<br>96 RLT (Qiagen) and stored at -80 for 94 described previously[29]. Two curette samples were collected into PBS + 5mM EDTA and 0.5% heat<br>95 inactivated FBS for immunophenotyping and an additional two curette samples were collected into<br>96 RLT (Qiagen) and stor 95 inactivated FBS for immunophenotyping and an additional two curette samples were collected into<br>96 RLT (Qiagen) and stored at -80 for transcriptome analysis. In the microbiopses, nasal epithelial cells<br>96 RLT (Qiagen) a 96 RLT (Qiagen) and stored at -80 for transcriptome analysis. In the microbiopses, nasal epithelial cells<br>96 RLT (Qiagen) and stored at -80 for transcriptome analysis. In the microbiopses, nasal epithelial cells  $\mathcal{R}(\mathbf{x}, \mathbf{g}, \mathbf{r})$  and stored at -80 for transcriptome analysis. In the microbiopses, nasal epithelial cells

97 Followed by a monoclonal antibody cocktail (Supplementary Table 1). Samples were acquired on a<br>
199 LSR II cytometer (BD Biosciences) and analysed using Flowjo software version 10 (Treestar).<br>
199 Compensation matrices wer ESR II cytometer (BD Biosciences) and analysed using Flowjo software version 10 (Treestar).<br>
199 Eompensation matrices were set using compensation beads (BD Biosciences and Thermofisher).<br>
199 Samples with less than 500 CD Compensation matrices were set using compensation beads (BD Biosciences and Thermofisher).<br>
99 Compensation matrices were set using compensation beads (BD Biosciences and Thermofisher).<br>
99 Comples with less than 500 CD45+ 101 Samples with less than 500 CD45+ leukocytes or 250 EpCam+ epithelial cells were excluded from<br>102 analysis. To adjust for the variability of cells collected within and between study participants,<br>103 absolute cell coun 2012 Empere minister manners terms temptop is the completed within and between study participants,<br>103 absolute cell counts of the target populations were normalized with the absolute number of<br>104 epithelial cells. The ga 103 absolute cell counts of the target populations were normalized with the absolute number of<br>104 epithelial cells. The gating strategy is shown in Supplementary Fig. 1.<br>105 **Nasal Cell RNA Sequencing and Bioinformatic An** 

epithelial cells. The gating strategy is shown in Supplementary Fig. 1.<br>
105 **Nasal Cell RNA Sequencing and Bioinformatic Analysis**<br>
106 *RNA sequencing*: Nasal cells were collected in RLT (QIAGEN) and stored at -80°C unti 105 **Nasal Cell RNA Sequencing and Bioinformatic Analysis**<br>106 RNA sequencing: Nasal cells were collected in RLT (QIAGEN) and store<br>107 extraction (RNeasy; QIAGEN), sample integrity assessment (Bioa<br>108 preparation and RNA 105 Nasal Cell RNA Sequencing and Biomomulatic Analysis<br>106 RNA sequencing: Nasal cells were collected in RLT (QIAG<br>107 extraction (RNeasy; QIAGEN), sample integrity asse:<br>108 preparation and RNA sequencing (BGISEQ-500RS) 2008 RNA sequencing: Nasal cells were collected in RLT (QIAGEN) and stored at 50°C until extraction. KIM<br>2008 extraction (RNeasy; QIAGEN), sample integrity assessment (Bioanalyzer; Agilent 2100), library<br>2009 RNA mapping a method and RNA sequencing (BGISEQ-500RS) were performed at the Beijing Genome Institute.<br>
109 RNA mapping and annotation: Quality control of raw sequencing data was conducted using the<br>
110 FastQC tool. The human reference 108 RNA mapping and annotation: Quality control of raw sequencing data was conducted using th<br>
110 FastQC tool. The human reference genome assembly GRCh38 was mapped using STAR 2.5.0a [30<br>
111 Read counts from binary align FastQC tool. The human reference genome assembly GRCh38 was mapped using STAR 2.5.0a [30].<br>111 Read counts from binary alignment map (BAM) files were obtained using featureCounts [31] utilizing<br>112 a general transfer forma Read counts from binary alignment map (BAM) files were obtained using featureCounts [31] utilizing<br>112 a general transfer format (GTF) gene annotation from the Ensembl database [32]. The<br>113 R/Bioconductor package DESeq2 ( 112 a general transfer format (GTF) gene annotation from the Ensembl database [32]. The<br>113 R/Bioconductor package DESeq2 (version 1.34.0) was used for identifying differentially expressed<br>114 genes, excluding features abs

113 R/Bioconductor package DESeq2 (version 1.34.0) was used for identifying differentially expressed<br>114 genes, excluding features absent in more than 75% of samples[33].<br>115 Functional analysis: Gene Set Enrichment Analys 114 genes, excluding features absent in more than 75% of samples[33].<br>115 Functional analysis: Gene Set Enrichment Analysis (GSEA) was conducted to identify significant<br>116 pathways in the ranked transcriptome (log2 fold-c Eunctional analysis: Gene Set Enrichment Analysis (GSEA) was contained than 7116 pathways in the ranked transcriptome (log2 fold-change multiplied<br>117 of the differential expression cut-off [34], using the R package fgse<br>1 pathways in the ranked transcriptome (log2 fold-change multiplied by -log10 p-values), independent<br>117 of the differential expression cut-off [34], using the R package fgsea (version 1.20.0) [35]. Pathways<br>118 with a p-val 117 of the differential expression cut-off [34], using the R package fgsea (version 1.20.0) [35]. Pathways<br>118 with a p-value < 0.05 and an enrichment of at least five genes were considered statistically<br>119 significant. T with a p-value < 0.05 and an enrichment of at least five genes were considered statistically<br>119 significant. The Reactome database (release 79) and Pathway Browser (version 3.750) were used for<br>120. Initial expression con 119 significant. The Reactome database (release 79) and Pathway Browser (version 3.750) were used for<br>120 this analysis [36]. Heatmap plots were generated using the R package pheatmap (version 1.0.12).<br>121 Statistical anal

120 this analysis [36]. Heatmap plots were generated using the R package pheatmap (version 1.0.12).<br>121 Statistical analysis and Correlation plots<br>122 Participant characteristics were summarised as n, median (interquartile Statistical analysis and Correlation plots<br>122 Participant characteristics were summarised as n, median (interquartile range) or freque<br>123 (percentage). Chi-squared test and Fisher's exact test were conducted to identify 121 Statistical analysis and Correlation plots<br>122 Participant characteristics were summi<br>123 (percentage). Chi-squared test and Fishi<br>124 changes in categorical variables. Non-pa<br>125 were conducted to compare quantitativ<br> 123 (percentage). Chi-squared test and Fisher's exact test were conducted to identify any significant<br>124 changes in categorical variables. Non-parametric Wilcoxon paired tests and Mann-Whitney tests<br>125 were conducted to 124 changes in categorical variables. Non-parametric Wilcoxon paired tests and Mann-Whitney tests<br>
125 were conducted to compare quantitative data within the same group or between two groups,<br>
126 respectively. In additio The conducted to compare quantitative data within the same group or between two groups,<br>126 changes in addition, Kruskal–Wallis rank-sum test with Dunn's correction were performed to<br>127 compare quantitative data amongst 126 respectively. In addition, Kruskal–Wallis rank-sum test with Dunn's correction were performed to<br>
127 compare quantitative data amongst groups (three groups comparison). Tests were two sided with<br>
128 an  $\alpha$  level of 127 compare quantitative data amongst groups (three groups comparison). Tests were two-sided with<br>128 an α level of 0.05. For correlations, two-tailed Pearson's or Spearman's r test was used. To explore<br>129 the associati 2128 an a level of 0.05. For correlations, two-tailed Pearson's or Spearman's r test was used. To explore<br>129 the association between time after infection and vaccination, we employed a linear regression<br>129 the associatio 129 an a level of 0.05. For correlations, two-tailed Pearson's or Spearman's r test was used. To explore<br>129 the association between time after infection and vaccination, we employed a linear regression

129 the association between time after infection and vaccination, we employed a linear regression

130

Vienna, Austria), using rstatix package (version 4.2.3) or in Graphpad Prism version 9.0.<br>
132 Correlograms plotting the Spearman rank correlation coefficient (r), between all parameter pairs<br>
133 were created with the cor 132 Correlograms plotting the Spearman rank correlation coefficient (r), between all parties were created with the corrplot package (v0.84) running under R (v3.6.1) in R student Clustering of parameters was performed usin were created with the corrplot package (v0.84) running under R (v3.6.1) in R studio (1.1.456).<br>
134 Clustering of parameters was performed using the 'hclust' option of corrMatOrder. Spearman rank<br>
135 two-tailed P values 134 Clustering of parameters was performed using the 'hclust' option of corrMatOrder. Spearman rank<br>
135 two-tailed P values were calculated using corr.test (psych v1.8.12) and graphed (ggplot2 v3.1.1)<br>
136 based on \* p < 135 two-tailed P values were calculated using corr.test (psych v1.8.12) and graphed (ggplot2 v3.1.1)<br>136 based on \* p < 0.05, \*\*p < 0.01, \*\*\* p < 0.001.<br>137<br>**RESULTS** the finite P value interestion and graphed (psychological psychological correspondence on a position of the value<br>135 RESULTS<br>139 Asymptomatic viral infection of the upper airways with RSV and rhinovirus predisposes to

## based on \*p < 0.05, \*p < 0.01, \*p < 0.001.<br>137<br>138 **RESULTS**<br>139 Asymptomatic viral infection of the upper a<br>140 pneumococcal carriage acquisition.

138<br>139<br>140<br>141 138 **Asympto**<br>140 **pneumod**<br>141 Cross-sec<br>142 revealed 139 Asymptomatic viral infection of the upper antways with RSV and rhinovirus predisposes to<br>140 **preumococcal carriage acquisition.**<br>141 Cross-sectional analysis of naso/oropharyngeal samples collected from healthy adults meanioececal carriage acquisition.<br>141 Cross-sectional analysis of naso/ord<br>142 revealed that 17% (99/581) of the<br>143 virus before pneumococcal challeng<br>144 during autumn and winter months (0<br>145 single virus were detected 142 revealed that 17% (99/581) of the individuals were asymptomatically infected with a respiratory<br>143 virus before pneumococcal challenge (Figure 1A). These asymptomatic URTIs were more frequent<br>144 during autumn and win 143 virus before pneumococcal challenge (Figure 1A). These asymptomatic URTIs were more frequent<br>144 during autumn and winter months (October – January) (Suppl. Figure 3A). Only infections caused by<br>145 single virus were d during autumn and winter months (October – January) (Suppl. Figure 3A). Only infections caused by<br>145 single virus were detected, with rhinovirus (RH) being the most frequent (7.6%), followed by<br>146 seasonal coronaviruses 145 single virus were detected, with rhinovirus (RH) being the most frequent (7.6%), followed by<br>146 seasonal coronaviruses (hCoV, 4%), whereas RSV-A/RSV-B, parainfluenza viruses (PIVs) and<br>147 adenovirus were less frequen single virus of the monoralistics (ACoV, 4%), whereas RSV-A/RSV-B, parainfluenza viruses (PIVs) and<br>147 adenovirus were less frequently detected (Figure 1A and Table 1), possibly as they are frequently<br>148 symptomatic and

147 adenovirus were less frequently detected (Figure 1A and Table 1), possibly as they are frequently<br>148 symptomatic and therefore participants would have been excluded prior to enrolment.<br>149 Experimentally induced pneum 148 symptomatic and therefore participants would have been excluded prior to enrolment.<br>
149 Experimentally induced pneumococcal colonisation was detected in 291 out of the 581 participants<br>
150 (50%), as assessed by longi Experimentally induced pneumococcal colonisation was detected in 291 out of the 58:<br>
(50%), as assessed by longitudinal analysis of the nasal wash samples post challenge a<br>
common among female participants (56% female vs 4 150 (50%), as assessed by longitudinal analysis of the nasal wash samples post challenge and was more<br>151 common among female participants (56% female vs 41% male, p=0.009), as reported previously<br>152 [37]. Analysis of the 151 common among female participants (56% female vs 41% male, p=0.009), as reported previously<br>152 [37]. Analysis of the asymptomatic URT cases based on carriage outcome (Spn-colonised and non-<br>153 colonised group) showed 152 [37]. Analysis of the asymptomatic URT cases based on carriage outcome (Spn-colonised and non-<br>153 colonised group) showed a differential distribution of respiratory viruses between the two groups.<br>154 RH, RSV and PIV  $152$   $372$   $372$   $372$  cases based on cases based on cases based on cases based and non-colonised and non-coloni 154 RH, RSV and PIV were more apparent in those that become colonised after challenge (Figure 1C)<br>155 compared to those who remained non-colonised (Figure 1B). In presence of any respiratory virus in<br>156 the naso/oropharyn 155 compared to those who remained non-colonised (Figure 1B). In presence of any respiratory virus in<br>156 the naso/oropharynx prior to challenge, pneumococcal carriage increased from 49% (235 out of 482<br>157 virus-negative 156 the naso/oropharynx prior to challenge, pneumococcal carriage increased from 49% (235 out of 482<br>157 virus-negative individuals) to 57% (56 out of 99 virus-positive individuals) (Figure 1D). Assessment of<br>158 the effec 157 the nasty reprint, the prior or materials, present control carriers in the nasty prior to change increased the effect of individuals) to 57% (56 out of 99 virus-positive individuals) (Figure 1D). Assessment of the effe 158 the effect of individual viral species on carriage acquisition revealed that URTI with certain viruses,<br>159 such as rhinovirus and RSV, likely PIVs but not HCoVs predispose individuals to pneumococcal<br>160 colonisation 159 such as rhinovirus and RSV, likely PIVs but not HCoVs predispose individuals to pneumococcal<br>
160 colonisation (Figure 1E). RH-, RSV- and PIV-infected groups reached colonisation rates of 66% (29/44,<br>
161 p=0.035), 88 160 colonisation (Figure 1E). RH-, RSV- and PIV-infected groups reached colonisation rates of 66% (29/44,<br>161 p=0.035), 88% (7/8, p=0.035) and 71% ((5/7, p=0.26), respectively, compared to 49% observed in the<br>161 p=0.035) 161 p=0.035), 88% (7/8, p=0.035) and 71% ((5/7, p=0.26), respectively, compared to 49% observed in the<br>p=0.035), 88% (7/8, p=0.035) and 71% ((5/7, p=0.26), respectively, compared to 49% observed in the  $\mathbf{r} = (\mathbf{r}, \mathbf{r}, \mathbf{r})$ ,  $\mathbf{r} = (\mathbf{r}, \mathbf{r}, \mathbf{r})$ , parameters,  $(\mathbf{r}, \mathbf{r}, \mathbf{r})$ , respectively, respectively, respectively, and  $\mathbf{r} = (\mathbf{r}, \mathbf{r}, \mathbf{r})$ ,  $\mathbf{r} = (\mathbf{r}, \mathbf{r}, \mathbf{r})$ ,  $\mathbf{r} = (\mathbf{r}, \mathbf{r}, \mathbf{r$ 

162

163 0.035) in the RH infected group, 5.3 (95% CI: 0.90 – 30.61, p = 0.034) in the RSV infected group and<br>164 2.63 (95% CI: 0.56 – 13.3, p=0.26) in the PIV infected group (Table 2).<br>165 We also investigated whether URT vir 2.63 (95% CI: 0.56 – 13.3, p=0.26) in the PIV infected group (Table 2).<br>165 We also investigated whether URT viral infection influences the pneumococcal colonising density.<br>166 The area under the curve (AUC) of pneumococca We also investigated whether URT viral infection influences the pn<br>166 – The area under the curve (AUC) of pneumococcal colonising density<br>167 – virus positive compared to the virus negative group for the Day 2 to D<br>168 – The area under the curve (AUC) of pneumococcal colonising density was significantly higher in the<br>167 Virus positive compared to the virus negative group for the Day 2 to Day 7 [median, IQR: 13.38 (5.82-<br>168 20.21) vs 8.47 167 Virus positive compared to the virus negative group for the Day 2 to Day 7 [median, IQR: 13.38 (5.82-<br>168 20.21) vs 8.47 (5.2-14.15), p=0.007) and Day2 to Day14 interval post challenge [33.12 (16.25-42.16)<br>169 vs 20.40 217 virus positive compared to the virus negative group (step terms experience) the virus negative compared to Day 14 interval post challenge [33.12 (16.25-42.16) vs 20.40 (11.01-30.11), p=0.008] (Figure 1F). Comparison of 168 20.40 (11.01-30.11), p=0.008] (Figure 1F). Comparison of colonisation density kinetics up to D21 post challenge between virus negative individuals and those infected with HCoV, Rhinovirus or RSV suggested that the pres 170 post challenge between virus negative individuals and those infected with HCoV, Rhinovirus or RSV<br>171 suggested that the presence of any respiratory virus can have a transient effect towards increased<br>172 bacterial de 171 suggested that the presence of any respiratory virus can have a transient effect towards increased<br>172 bacterial density (Figure 2G-I). Amongst different viruses, presence of RSV in the nasopharynx had<br>173 the most st bacterial density (Figure 2G-I). Amongst different viruses, presence of RSV in the nasopharynx had<br>173 the most striking effect, as increased pneumococcal density by 2-log at D2 compared to virus<br>174 negative group (media 173 the most striking effect, as increased pneumococcal density by 2-log at D2 compared to virus<br>174 negative group (median, SEM: 3.76 ± 0.65 vs 1.79 ± 0.09) (p= 0.02) an observation that continued up<br>175 to D9 post chall 174 negative group (median, SEM:  $3.76 \pm 0.65$  vs  $1.79 \pm 0.09$ ) (p= 0.02) an observation that continued up<br>175 to D9 post challenge (Figure 2H). We also observed that seasonality affected colonising density in<br>176 the vi 175 to D9 post challenge (Figure 2H). We also observed that seasonality affected colonising density in<br>176 the viral infected group. Increased prevalence of viral URTI in Autumn and Winter months was<br>177 followed by an in 176 the viral infected group. Increased prevalence of viral URTI in Autumn and Winter months was<br>177 followed by an increased in pneumococcal density during the same period of the year (Suppl. Figure<br>180. Distinct need inf 177 the viral infected group. Increased in phermatic of viral URT increasing and winter months was<br>178 18).<br>179 Distinct nasal inflammatory profile in those with asymptomatic URT infection 178 followed by an increased production annihipsing in the princreased in p<sub>partic</sub> or the period of the year (Supple. Figure<br>179 **Distinct nasal inflammatory profile in those with asymptomatic URT infection**<br>181 Levels of

--- ---,<br>179<br>180 **Disti**<br>181 Leve<br>182 the 180<br>181<br>182<br>183 Levels of nasal inflammation induced by viral infection were assessed by meas<br>the nasal wash samples collected before exposure to pneumococcus (screeni<br>divided in three groups based on the type of viral infection (HCoV, RH 182 the nasal wash samples collected before exposure to pneumococcus (screening). Individuals were<br>183 divided in three groups based on the type of viral infection (HCoV, RH, RSV) and compared to the<br>184 non-infected group divided in three groups based on the type of viral infection (HCoV, RH, RSV) and compared to the<br>184 non-infected group (virus negative group) (Figure 2). Infection with RH, even in absence of<br>185 symptoms, elicited an acu 184 non-infected group (virus negative group) (Figure 2). Infection with RH, even in absence of<br>185 symptoms, elicited an acute nasal inflammatory response, with strong induction of pro-<br>186 inflammatory mediators (TNFa, I 185 symptoms, elicited an acute nasal inflammatory response, with strong induction of pro-<br>186 inflammatory mediators (TNFa, IL6 and IL1b), monocyte recruiting chemokines (MIP-1a, MIP-1b) and<br>187 substantial increase in se  $185$  symptoms, elicited and acute nasal inflammatory response, with strong induction of prosubstantial increase in several antiviral mediators, such as type I, II and II interferons, granzyme A,<br>188 IP10 and MIG. Asymptomatic infection with seasonal coronaviruses (apha- or beta-coronavirus)<br>189 induced a similar 188 IP10 and MIG. Asymptomatic infection with seasonal coronaviruses (apha- or beta-coronavirus)<br>189 induced a similar type of nasal inflammation compared to RH infection, but overall weaker. RSV had<br>190 a relatively mild induced a similar type of nasal inflammation compared to RH infection, but overall weaker. RSV had<br>
190 a relatively mild inflammatory profile, the least pro-inflammatory amongst the three types of URTI,<br>
191 which was cha a relatively mild inflammatory profile, the least pro-inflammatory amongst the three types of URTI,<br>191 which was characterized by absence of chemokine induction and a relatively weak antiviral<br>192 response. Despite of dif 191 which was characterized by absence of chemokine induction and a relatively weak antiviral<br>192 response. Despite of differences introduced due to virus type and infection time, 9 cytokines (GM-<br>193 CSF, Granzyme A, IFN-192 response. Despite of differences introduced due to virus type and infection time, 9 cytokines (GM-<br>193 CSF, Granzyme A, IFN-g, IL-2, IL33, IL-4, IL10, IL-6 and TNF-a) were identified as commonly induced in<br>194 all asym all asymptomatic URTIs. Inflammatory responses per group were also stratified and analysed based<br>all asymptomatic URTIs. Inflammatory responses per group were also stratified and analysed based<br>of the stratified induced in 194 all asymptomatic URTIS. Inflammatory responses per group were also stratified and analysed based and analysed<br>The contract of the contract

195 196 inflammatory mediators are associated with susceptibility to Spn carriage acquisition. In the studied<br>197 cohort, there was no differentially expressed cytokines between those that would become colonised<br>198 and those 197 cohort, there was no differentially expressed cytokines between those that would become colonised<br>198 and those aborted colonisation in each viral group separately or in the combined viral infected<br>199 groups (data not 198 and those aborted colonisation in each viral group separately or in the combined viral infected<br>199 groups (data not shown).<br>200 **Route of bacterial shedding and association with colonising density**<br>201 In a subset (n=

199 and those above).<br>199 and those above).<br>199 **Route of bacterial shedding and association with colonising density**<br>199 and some parately of participants (all individuals enrolled into two consecutive studies from 2018 t 200 **Route of bacterial sheddi**<br>201 In a subset (n=169) of par<br>202 2019) we investigated back<br>203 hand samples (Suppl. Figu 200 Route of bacterial shedding and association with colonising density<br>201 In a subset (n=169) of participants (all individuals enrolled into two co<br>202 2019) we investigated bacterial shedding through the mouth and nos<br>2 202 2019) we investigated bacterial shedding through the mouth and nose collecting cough and nose-to-<br>203 hand samples (Suppl. Figure 1), irrespective of the carriage outcome. Bacterial shedding by any route<br>204 required s 202 2019) we investigated bacterial shedding through the mouth and nose collecting cough and nose-to-204 required successful colonisation after the bacterial challenge at D0. None of the non-colonised<br>205 individuals (n=48) had a positive shedding sample. Amongst the Spn-colonised (n=121), we identified<br>206 47 Spn-shedde 205 individuals (n=48) had a positive shedding sample. Amongst the Spn-colonised (n=121), we identified<br>206 47 Spn-shedders, who shed bacterial via the nose and/or mouth at any time point post challenge<br>207 and 74 non-she 206 47 Spn-shedders, who shed bacterial via the nose and/or mouth at any time point post challenge<br>207 and 74 non-shedders. In the Spn-shedders group, 64% (30/47) expired bacterial via the nose (nose-<br>208 shedders), 32% (1 207 and 74 non-shedders. In the Spn-shedders group, 64% (30/47) expired bacterial via the nose (nose-<br>208 shedders), 32% (15/47) via the mouth while coughing (cough-shedders) and only 4% (2/47) via both<br>209 routes simultan 213 density increased, reaching 80 and 80% in the highest density increments (10<sup>4</sup>-10<sup>5</sup> and 10<sup>5</sup>-10<sup>6</sup> 209 routes simultaneously (Figure 3A). Bacterial colonising density was consistently higher in the nose-<br>210 shedders compared to non-shedders group (Figure 3B). Further analysis of bacterial shedding in<br>211 association w  $2099 \times 34$  routes simultaneously (Figure 3A). Bacterial colonising density was consistently higher in the noseassociation with bacterial colonising density revealed a differential profile for cough- and nose-<br>212 shedders. A gradual increase in the proportion of nose-shedders was observed when bacterial<br>213 density increased, reac  $2112$  association with bacterial colonising density revealed a differential profile for coupl-213 density increased, reaching 80 and 80% in the highest density increments (10<sup>4</sup>-10<sup>5</sup> and 10<sup>5</sup>-10<sup>6</sup><br>214 CFU/ml of NW, respectively) (Figure 3C and Table 3). In addition, the number of expired bacteria via<br>215 the nos density increased, reaching 80 and 80% in the highest density increments (10<sup>+</sup><br>CFU/ml of NW, respectively) (Figure 3C and Table 3). In addition, the number of ex<sub>l</sub><br>the nose (shedding density) at any time point was strong -10°<br>pireo<br>ena<br>tin<br>also and  $10<sup>3</sup>$ <br>d bacteria<br>asal bacteria<br>fluenced<br>relatively<br>observe density increased, reaching 80 and 80% in the highest density increments (10°-10° and 10°-10°<br>214 CFU/ml of NW, respectively) (Figure 3C and Table 3). In addition, the number of expired bacteria via<br>215 the nose (shedding 215 the nose (shedding density) at any time point was strongly correlated with the nasal bacterial<br>216 density (Figure 3D) (R=0.52, p=0.0004). Contrarily, cough-shedding was not influenced by<br>217 fluctuations in nasal bac 216 density (Figure 3D) (R=0.52, p=0.0004). Contrarily, cough-shedding was not influenced by<br>217 fluctuations in nasal bacterial density, as the proportion of cough-shedders remained relatively low<br>218 in all density incre 217 fluctuations in nasal bacterial density, as the proportion of cough-shedders remained relatively low<br>218 in all density increments (Figure 3C and Table 3). This differential pattern was also observed in<br>219 relation to 218 in all density increments (Figure 3C and Table 3). This differential pattern was also observed in<br>219 relation to time post inoculation. Nose-shedders tended to shed bacteria predominately at D2 (72%,<br>220 23/32) and D6 relation to time post inoculation. Nose-shedders tended to shed bacteria predominately at D2 (72%,<br>220 23/32) and D6 (60%, 19/32) post inoculation; time points with highest mean densities (Figure 3F),<br>221 whereas shedding

220 23/32) and D6 (60%, 19/32) post inoculation; time points with highest mean densities (Figure 3F),<br>221 whereas shedding via cough was occurred evenly across time points (Figure 3E-F).<br>222 We also investigated the contri 221 Whereas shedding via cough was occurred evenly across time points (Figure 3E-F).<br>222 We also investigated the contribution of respiratory viruses in bacterial shedding, due to previously<br>223 observed associations with 222 We also investigated the contribution of respiratory viruses in bacterial shedding,<br>223 observed associations with density changes and induction of nasal inflamm<br>224 Coronaviruses was detected only in the non-shedders 223 observed associations with density changes and induction of nasal inflammatory responses.<br>224 Coronaviruses was detected only in the non-shedders group in a proportion of 8% (6/74), rhinovirus<br>225 was found in similar 224 Coronaviruses was detected only in the non-shedders group in a proportion of 8% (6/74), rhinovirus<br>225 was found in similar proportion in shedders and non-shedders, whereas RSV and HPIVs was detected<br>226 in a small pro 225 was found in similar proportion in shedders and non-shedders, whereas RSV and HPIVs was detected<br>226 in a small proportion (3%, 1/30) of nose-shedders only. There was no difference in viral copies<br>227 detected in Spn-s 226 in a small proportion (3%, 1/30) of nose-shedders only. There was no difference in viral copies<br>227 detected in Spn-shedders and non-shedders (Suppl. Figure 4A). However, Spn-shedders with<br>227 detected in Spn-shedders 227 detected in Spn-shedders and non-shedders (Suppl. Figure 4A). However, Spn-shedders with<br>227 detected in Spn-shedders and non-shedders (Suppl. Figure 4A). However, Spn-shedders with 227 detected in Spn-shedders and non-shedders (Suppl. Figure 4A). However, Spn-shedders with

228 229 inoculation compared to non-shedders with (Suppl. Figure 4B). The small numbers of individuals<br>230 with confirmed asymptomatic URT and shedding data limited further investigation of the role of viral<br>231 infection in s with confirmed asymptomatic URT and shedding data limited further investigation of the role of viral<br>231 infection in shedding.<br>232 **Distinct nasal cell profile and gene expression patterns in nose-shedders**<br>233 We next an

231 infection in shedding.<br>232 Distinct nasal cell profile and gene expression patterns in nose-shedders<br>233 We next analysed the cellular composition of nasal cells obtained by nasal microbiopsies, applying<br>234 flow cytom 232 **Distinct nasal cell pro**<br>233 We next analysed the<br>234 flow cytometry. The n<br>235 epithelial cells [20] an 232 Distinct nasal cell profile and gene expression patterns in nose-shedders<br>233 We next analysed the cellular composition of nasal cells obtained by nas<br>234 flow cytometry. The number of leukocytes, granulocytes and mono 234 flow cytometry. The number of leukocytes, granulocytes and monocytes was expressed as a ratio to<br>235 epithelial cells [20] and compared between the three Spn-colonised groups at baseline, day2, day6<br>236 and day16 post 235 epithelial cells [20] and compared between the three Spn-colonised groups at baseline, day2, day6<br>236 and day16 post pneumococcal challenge (Figure 4A). At baseline, overall levels of nasal immune cells<br>237 were compar 236 and day16 post pneumococcal challenge (Figure 4A). At baseline, overall levels of nasal immune cells<br>237 were comparable amongst the groups, with the exception of CD8<sup>+</sup> T cells levels (Figure 4A). After<br>238 challenge, were comparable amongst the groups, with the exception of CD8<sup>\*</sup> T cells levels (Figure 4A). After<br>
challenge, nose-shedders had a substantial increase in the proportion of neutrophils compared to<br>
239 non-shedders and in were comparable amongst the groups, with the exception of CD8<sup>.</sup> T cells levels (Figure 4A). After<br>
challenge, nose-shedders had a substantial increase in the proportion of neutrophils compared to<br>
non-shedders and in mono 239 non-shedders and in monocytes and CD4<sup>+</sup> T cells compared to both cough- and non-shedders. This<br>240 increase in immune cells was observed only at 2 days post challenge and only in the nose-shedders<br>241 group.<br>242 Nasal

non-shedders and in monocytes and CD4<sup>.</sup> T cells compared to both cough- and non-shedders. This<br>240 increase in immune cells was observed only at 2 days post challenge and only in the nose-shedders<br>241 group.<br>242 Nasal cel 241 group.<br>242 Nasal cells were also obtained from the same individuals for a parallel transcriptome analysis (Figure<br>243 4B). Genes transcriptional changes in cough- and nose-shedders per time point post challenge were<br>24 242 Nasal c<br>243 4B). Ge<br>244 describ<br>245 gene se<br>245 gene se 243 4B). Genes transcriptional changes in cough- and nose-shedders per time point post challenge were<br>244 described in relation to non-shedders as the reference group. Cough-shedders had an enrichment in<br>245 gene sets asso 244 described in relation to non-shedders as the reference group. Cough-shedders had an enrichment in<br>245 gene sets associated with innate immune responses and cytokine signalling at the very early stages<br>246 of pneumococc gene sets associated with innate immune responses and cytokine signalling at the very early stages<br>246 of pneumococcal colonisation (day 2 PI), which was dismissed at later time points. In nose-shedders,<br>247 adaptive immun 246 of pneumococcal colonisation (day 2 PI), which was dismissed at later time points. In nose-shedders,<br>247 adaptive immunity gene sets and cytokines signalling were upregulated early after colonisation,<br>248 whereas enric adaptive immunity gene sets and cytokines signalling were upregulated early after colonisation,<br>248 whereas enrichment in innate immune system gene sets was delayed (day 16 PI).<br>250 **Nasal inflammation drives bacterial she** 

248 whereas enrichment in innate immune system gene sets was delayed (day16 PI).<br>249 **Nasal inflammation drives bacterial shedding through the nose.**<br>251 Nasal inflammation was also assessed by measuring the levels of 30 c 249<br>250 **Nasal inflammation drives bacterial shedding through the nose.**<br>251 Nasal inflammation was also assessed by measuring the levels of 30 cytokines inose- and cough-shedders at four time points (D2, D6, D16 and D22) ---<br>250<br>251<br>252<br>253<br>254 250 Nasal inflammation drives bacterial shedding through the nose.<br>251 Nasal inflammation was also assessed by measuring the levels c<br>252 nose- and cough-shedders at four time points (D2, D6, D16 and<br>253 with the levels me 252 nose- and cough-shedders at four time points (D2, D6, D16 and D22) post-challenge and compared<br>253 with the levels measured in non-shedders at the same time points. Nose-shedders had a distinct pro-<br>254 inflammatory pr with the levels measured in non-shedders at the same time points. Nose-shedders had a distinct pro-<br>254 inflammatory profile, defined by enrichment in growth factors, pro-inflammatory cytokines (IL-1b<br>255 and TNFa) and che 253 with the levels measured in non-shedders at the same time points. Nose-shedders had a distinct pro-255 and TNFa) and chemokines that affect monocytes and granulocytes migration, such as macrophage-<br>256 inflammatory protein-1a and -1b (MIP-1a, MIP-1b) and granulocyte-colony stimulation factor (G-<br>257 CSF). This increase 258 at D2 (upregulation of 9 out of 30 cytokines), D6 and D16 (upregulation of 7 out of 30 cytokines) but<br>259 not at D22 post-challenge. On the other hand, cough-shedders did not differ from their non-shedder<br>259 not at D2 259 at D22 post-challenge. On the other hand, cough-shedders did not differ from their non-shedder  $\frac{1}{2}$  out of 30 cytokines) but of 30 cytokines and D22 post-challenge. On the other hand, cough-shedders did not diffe 259 not at D22 post-challenge. On the other hand, cough-shedders did not differ from their non-shedder

260

261 colonisation.<br>262 Acute nasal inflammation was identified as a key characteristic of nasal bacterial shedding, as in the<br>263 case of pneumococcal density. To dissect the associations between nasal inflammatory response 262 Acute nasal in<br>263 case of pneu<br>264 bacterial col<br>265 correlation pl<br>266 and D6 post-263 case of pneumococcal density. To dissect the associations between nasal inflammatory responses,<br>264 bacterial colonising density and bacterial shedding, these parameters were analysed using<br>265 correlation plots for th 264 bacterial colonising density and bacterial shedding, these parameters were analysed using<br>265 correlation plots for the time points wherein bacterial shedding was more frequently observed (D2<br>266 and D6 post-infection) 265 correlation plots for the time points wherein bacterial shedding was more frequently observed (D2<br>266 and D6 post-infection). Notably, correlation plots indicated a positive association between nasal<br>267 inflammatory r 266 and D6 post-infection). Notably, correlation plots indicated a positive association between nasal<br>267 inflammatory responses and bacterial shedding through the nose. At day 2 post-challenge, the<br>268 association with in 267 inflammatory responses and bacterial shedding through the nose. At day 2 post-challenge, the association with inflammatory responses included pro-inflammatory cytokines (IL-6, TNFa, IL-1RA) and the involvement of sever association with inflammatory responses included pro-inflammatory cytokines (IL-6, TNFa, IL-1RA)<br>269 and the involvement of several monocyte and granulocytes chemokines and growth factors<br>270 [monocyte-chemoattractant prot 269 and the involvement of several monocyte and granulocytes chemokines and growth factors<br>270 [monocyte-chemoattractant protein-1 (MCP-1), MIP-1a, MIP-1b, MIG and granulocyte-monocyte<br>271 colony stimulation factor (GM-CSF 270 [monocyte-chemoattractant protein-1 (MCP-1), MIP-1a, MIP-1b, MIG and granulocyte-monocyte<br>271 colony stimulation factor (GM-CSF)] (Figure 5C), whereas at day 6 associations were restricted to<br>272 only 2 pro-inflammator 271 colony stimulation factor (GM-CSF)] (Figure 5C), whereas at day 6 associations were restricted to<br>272 only 2 pro-inflammatory cytokines (IL-6 and TNFa) (Figure 5D). A similar relationship was also<br>273 observed between 272 only 2 pro-inflammatory cytokines (IL-6 and TNFa) (Figure 5D). A similar relationship was also<br>273 observed between nasal inflammation and pneumococcal density, deriving mainly from pro-<br>274 inflammatory responses and 273 observed between nasal inflammation and pneumococcal density, deriving mainly from pro-<br>274 inflammatory responses and MCP-1 chemokine at Day 2 (Figure 5C) and was enriched with<br>275 additional chemoattract cytokines (M

278 context of disease (hospitalisation cases, pathogenicity) [10, 38] describing associations rather than 275 additional chemoattract cytokines (MIP-1a, MIP-1b, RANTES) at Day 6 post-challenge (Figure 5D).<br>276 **DISCUSSION**<br>277 In humans, respiratory viral and pneumococcal co-infections have mainly been studied in the<br>278 conte 276 **DISCUSSION**<br>277 In humans, respiratory viral and pneumococcal co-infections have mainly been studied in<br>278 context of disease (hospitalisation cases, pathogenicity) [10, 38] describing associations rather th<br>280 loca 276 DISCUSSION<br>278 context of discussion<br>279 a causative<br>280 leading to sul 278 context of disease (hospitalisation cases, pathogenicity) [10, 38] describing associations rather than<br>279 a causative relationship. How respiratory viruses influence pneumococcal carriage acquisition,<br>280 leading to s

279 a causative relationship. How respiratory viruses influence pneumococcal carriage acquisition,<br>280 leading to subsequent disease and bacterial transmission to the community, is not well described.<br>281 Here, we investig 280 leading to subsequent disease and bacterial transmission to the community, is not well described.<br>281 Here, we investigated the impact of natural viral URTI on acquisition of experimentally induced<br>282 colonisation and 281 Here, we investigated the impact of natural viral URTI on acquisition of experimentally induc<br>282 colonisation and have shown that primary infection with certain respiratory viruses, such<br>283 rhinovirus, RSV, PIVs, but 282 colonisation and have shown that primary infection with certain respiratory viruses, such as<br>283 rhinovirus, RSV, PIVs, but not seasonal coronaviruses, increased pneumococcal carriage rates. In<br>284 agreement with previ 283 colonisation and have shown that primary infection that sevent respiratory in the system in<br>284 consider and have shown that primary infection with certain respiratory viruses in the upper airways<br>285 also led to highe 284 agreement with previous reports[39, 40], presence of these respiratory viruses in the upper airways<br>285 also led to higher pneumococcal colonising density, with RSV infection having the most striking<br>286 effect. It is 285 also led to higher pneumococcal colonising density, with RSV infection having the most striking<br>286 effect. It is possible that viral infection and subsequent inflammation provide an environment,<br>287 enriched in nutrie

286 effect. It is possible that viral infection and subsequent inflammation provide an environment,<br>287 enriched in nutrients, promoting bacterial proliferation [41].<br>288 Our results support epidemiological and clinical ev effect. It is possible that in the sum of 1837<br>288 Our results support epidemiological and clinical evidence, suggesting that certain respiratory viruses,<br>289 May have a substantial role in the burden of pneumococcal disea 288 Our results support epidemiological and clinical evidence, support explained in the burden of pneumocod<br>290 acquired carriage episode poses an increased risk towards of<br>291 bost has not yet developed immunity to the pa 289 may have a substantial role in the burden of pneumococcal disease [8, 9, 38, 42-44]. A newly<br>290 acquired carriage episode poses an increased risk towards disease development, likely because the<br>291 host has not yet d 290 acquired carriage episode poses an increased risk towards disease development, likely because the<br>291 host has not yet developed immunity to the pathogen[45, 46]. Hence, a viral-induced pneumococcal<br>291 host has not y 291 bost has not yet developed immunity to the pathogen[45, 46]. Hence, a viral-induced pneumococcal<br>host has not yet developed immunity to the pathogen[45, 46]. Hence, a viral-induced pneumococcal  $291$  host has not yet developed immunity to the pathogen  $\mathcal{G}$  and  $\mathcal{G}$  viral-induced parameterization.

292

development, particularly in the at-risk populations, such as the very young, the old and the<br>294 immunocompromised.<br>295 RSV significant contribution to paediatric IPDs was recently highlighted by two surveillance studies<br> 294 immunocompromised.<br>295 RSV significant contribution to paediatric IPDs was recently highlighted by two surveillance studies<br>296 contacted in Israel[8] and France[9] during implementation of non-pharmaceutical intervent 295 RSV significant contribi<br>296 contacted in Israel[8]<br>297 early in COVID-19 pan<br>298 carriage in paediatrics v<br>299 study set-up and time 296 contacted in Israel[8] and France[9] during implementation of non-pharmaceutical interventions<br>297 early in COVID-19 pandemic. Both studies reported that the overall prevalence of pneumococcal<br>298 carriage in paediatri 297 early in COVID-19 pandemic. Both studies reported that the overall prevalence of pneumococcal<br>298 carriage in paediatrics was not significantly altered. This could be a result of population recruitment,<br>299 study set-u 298 carriage in paediatrics was not significantly altered. This could be a result of population recruitment,<br>299 study set-up and time of pneumococcal infection. Our study included healthy non-colonised adults,<br>200 who wer 299 study set-up and time of pneumococcal infection. Our study included healthy non-colonised adults,<br>200 who were experimentally exposed to pneumococcus at a known time, whereas the Israel and French<br>201 studies were both 209 who were experimentally exposed to pneumococcus at a known time, whereas the Israel and French<br>201 studies were both pneumococcal colonisation and IPD surveillance studies in children. RSV also has<br>202 been linked with 301 studies were both pneumococcal colonisation and IPD surveillance studies in children. RSV also has<br>302 been linked with increased pneumococcal invasiveness. Epidemiological data have reported<br>303 increased frequency of been linked with increased pneumococcal invasiveness. Epidemiological data have reported<br>303 increased frequency of less invasive, non-vaccine included, pneumococcal serotypes (15B/C, 33F),<br>304 during RSV infection in paed

303 increased frequency of less invasive, non-vaccine included, pneumococcal serotypes (15B/C, 33F),<br>304 during RSV infection in paediatric cases of community-acquired alveolar pneumonia [47]<br>305 On the other hand, there a 304 during RSV infection in paediatric cases of community-acquired alveolar pneumonia [47]<br>305 On the other hand, there are conflicting data on the relationship between rhinovirus and<br>306 parainfluenza infection and pneumo 305 On the other hand, there are conflicting data on the relationship between rhir parainfluenza infection and pneumococcal disease[8, 38, 39]. The balance swifts depen reported population, as those viral infections common 306 parainfluenza infection and pneumococcal disease[8, 38, 39]. The balance swifts depending on the<br>307 reported population, as those viral infections commonly associate with pneumococcal disease in<br>308 asthmatics, HIV in 307 reported population, as those viral infections commonly associate with pneumococcal disease in<br>308 asthmatics, HIV infected individuals and the elderly[38]. However, rhinoviral infection is very<br>309 common amongst chil 308 asthmatics, HIV infected individuals and the elderly[38]. However, rhinoviral infection is very<br>309 common amongst children and causes rhinitis[48], which in turn can lead to increased nasal<br>310 inflammation, and hence

309 common amongst children and causes rhinitis[48], which in turn can lead to increased nasal<br>310 inflammation, and hence pneumococcal shedding and onwards transmission during co-infection.<br>311 We also examined bacterial 310 inflammation, and hence pneumococcal shedding and onwards transmission during co-infection.<br>311 We also examined bacterial shedding through the nasal and oral route during experimentally<br>312 induced pneumococcal carria 311 We also examined bacterial shedding through the nasal and oral route during experiment<br>312 induced pneumococcal carriage. We have showed that pneumococci exit the host more freque<br>313 via the nose, early after establis 312 induced pneumococcal carriage. We have showed that pneumococci exit the host more frequently<br>313 via the nose, early after establishment of colonisation, predominantly when the nasopharynx is<br>314 inflamed and colonised via the nose, early after establishment of colonisation, predominantly when the nasopharynx is<br>314 inflamed and colonised with high bacterial load (Figure 6). In animal models, modulation of nasal<br>315 inflammation alters p 314 inflamed and colonised with high bacterial load (Figure 6). In animal models, modulation of nasal<br>315 inflammation alters pneumococcal shedding and transmission rates, indicating a direct relationship<br>316 of positive a 315 inflammation alters pneumococcal shedding and transmission rates, indicating a direct relationship<br>316 of positive association[19, 49]. Pneumolysin, a toxin produced and secreted by pneumococci, has<br>317 also been repor 316 of positive association[19, 49]. Pneumolysin, a toxin produced and secreted by pneumococci, has<br>317 also been reported as a significant factor that promotes inflammation and subsequently increased<br>318 bacterial sheddin 317 also been reported as a significant factor that promotes inflammation and subsequently increased<br>318 bacterial shedding[49]. Our results suggest that nasal shedding is more likely to occur during the<br>319 early stages o 318 bacterial shedding[49]. Our results suggest that nasal shedding is more likely to occur during the<br>319 early stages of a colonisation episode, when host innate immune responses, such as local<br>320 inflammation, neutroph Example and the dingtre process is a colonisation episode, when host innate immune responses, such as local<br>320 inflammation, neutrophils degranulation and phagocytes recruitment are at their peaks, as<br>321 previously obser 320 inflammation, neutrophils degranulation and phagocytes recruitment are at their peaks, as<br>321 previously observed in the human challenge model[20, 50]. An inflamed nasal mucosa can lead to<br>322 increased volume and flow 321 previously observed in the human challenge model[20, 50]. An inflamed nasal mucosa can lead to<br>322 increased volume and flow of secretions locally, promoting shedding and prolonged pneumococcal<br>323 survival in the env Fremently enterties in the human change model<sub>(20, 5</sub>0). The humanical much mucosary increased volume and flow of secretions locally, promoting shedding and prolonged pneumococcal survival in the environment [6, 49]. On th 323 survival in the environment [6, 49]. On the other hand, cough-induced shedding was dissociated<br>324 from host responses and bacterial density (Figure 6), allows to speculate that this route of shedding<br>324 from host re 324 from host responses and bacterial density (Figure 6), allows to speculate that this route of shedding from host responses and bacterial density (Figure 6), allows to speculate that this route of shedding  $3244$  from host responses and bacterial density (Figure 6), allows to speculate that this route of shedding  $\sim$  325 326 throat and oral cavity. In this study any association between viral URLT and bacterial shedding was<br>327 prohibited by the low numbers of viral-infected individuals in the nested shedding study, although<br>328 rhinoviral 327 prohibited by the low numbers of viral-infected individuals in the nested shedding study, although<br>328 thinoviral URLT was well represented in the shedders group. Also, viral-infected shedders were<br>329 colonised with h 238 rhinoviral URLT was well represented in the shedders group. Also, viral-infected shedders were<br>329 colonised with higher pneumococcal density compared to their non-shedder counterparts. Our<br>330 findings suggest that pn colonised with higher pneumococcal density compared to their non-shedder counterparts. Our<br>330 findings suggest that pneumococcal colonised adults, even when asymptomatic, may be a source of<br>331 contagion, particularly whe

330 findings suggest that pneumococcal colonised adults, even when asymptomatic, may be a source of<br>331 contagion, particularly when are heavily colonised, as in the case of viral co-infection.<br>332 Our study has limitation 2331 contagion, particularly when are heavily colonised, as in the case of viral co-infection.<br>332 Our study has limitations. Viral URTIs were naturally acquired and assessed by molecular methods<br>333 only before challenge, 332 Our study has limitations. Viral URTIs were naturally acquired and assessed by mole<br>333 only before challenge, and hence co-infection with pneumococcus may had occurr<br>334 point through the course of the primary viral i 333 only before challenge, and hence co-infection with pneumococcus may had occurred at any time<br>334 point through the course of the primary viral infection. In addition, only individuals with<br>335 asymptomatic URTI were en point through the course of the primary viral infection. In addition, only individuals with<br>335 asymptomatic URTI were enrolled into the challenge studies, as per studies inclusion/exclusion<br>336 criteria. The non-specified 335 asymptomatic URTI were enrolled into the challenge studies, as per studies inclusion/exclusion<br>336 criteria. The non-specified time of viral infection onset and the lack of symptoms may have masked<br>337 viral-induced na 336 criteria. The non-specified time of viral infection onset and the lack of symptoms may have masked<br>337 viral-induced nasal inflammation and the optimum effect that certain respiratory viruses have on<br>338 carriage acqui or a musical inference and the optimum effect that certain respiratory viruses have on<br>338 carriage acquisition. However, our results reflect some of the viral-pneumococcal associations<br>339 described in large epidemiologic carriage acquisition. However, our results reflect some of the viral-pneumococcal associations<br>339 described in large epidemiological studies, as in the case of highly influential RSV[8, 10, 51, 52] and<br>340 the ambiguous c described in large epidemiological studies, as in the case of highly influential RSV[8, 10, 51, 52] and<br>340 the ambiguous contribution of seasonal coronaviruses in secondary pneumococcal diseases [53, 54].<br>341 Another limi 340 the ambiguous contribution of seasonal coronaviruses in secondary pneumococcal diseases [53, 54].<br>341 Another limitation arises from the monomeric use of only pneumococcal serotype 6B, as challenge<br>342 agent. Further s 341 Another limitation arises from the monomeric use of only pneumococcal serotype 6B, as challenge<br>342 agent. Further studies are needed to investigate whether viral-pneumococcal relationship is<br>343 serotype dependent and 342 agent. Further studies are needed to investigate whether viral-pneumococcal relationship is<br>343 serotype dependent and whether during colonisation with other pneumococcal serotypes, the<br>344 bacterial exhibit the simila State the phemometrical pattern during colonisation with other pneumococcal serotypes, the<br>344 bacterial exhibit the similar or differential pattern of shedding. Another limitation is that we only<br>345 investigated one dire 344 bacterial exhibit the similar or differential pattern of shedding. Another limitation is that we only<br>345 investigated one direction of viral-bacterial relationship, with virus infection coming first. Further<br>346 studi 345 investigated one direction of viral-bacterial relationship, with virus infection coming first. Further<br>346 studies are needed to investigate the effects of a concurrent virus infection in an established<br>347 colonisatio 346 studies are needed to investigate the effects of a concurrent virus infection in an established<br>347 colonisation episode as well as how pneumococcus can impact on subsequent virus infections and<br>348 host responses.<br>359

Example are needed to investigate the effects of a concurrent intermediation in an established<br>348 studies are needed to subsequent virus infections and<br>348 The findings of this study suggest that protection against respir 348 host responses.<br>349 The findings of this study suggest that protection against respiratory viral infections and control of<br>350 pneumococcal density would have a major contribution in preventing pneumococcal disease and 349 The findings of 1<br>350 pneumococcal c<br>351 blocking bacter<br>352 outcome. Curi<br>353 cases[55], but th 350 pneumococcal density would have a major contribution in preventing pneumococcal disease and<br>351 blocking bacterial transmission. Vaccine interventions have the potential to confer this dual<br>352 outcome. Current licence 351 blocking bacterial transmission. Vaccine interventions have the potential to confer this dual<br>352 outcome. Current licenced pneumococcal conjugate vaccines have undoubtedly reduced IPD<br>353 cases[55], but their effect o 352 outcome. Current licenced pneumococcal conjugate vaccines have undoubtedly reduced IPD<br>353 cases[55], but their effect on pneumococcal colonisation density has been underestimated. Control<br>354 of pneumococcal density b Entranta current processes.<br>353 cases[55], but their effect on pneumococcal colonisation density has been underestimated. Control<br>354 of pneumococcal density by PCVs, as shown in experimentally colonised adults[56], can pl 354 of pneumococcal density by PCVs, as shown in experimentally colonised adults[56], can play a<br>355 pivotal role in preventing pneumococcal disease and reducing pneumococcal transmission. Yet, PCVs<br>356 protect against a l 2335 pivotal role in preventing pneumococcal disease and reducing pneumococcal transmission. Yet, PCVs protect against a limited number of the most invasive serotypes. After interaction with certain viruses, less invasive, process a process a limited number of the most invasive serotypes. After interaction with certain<br>357 viruses, less invasive, non-vaccine serotypes may exhibit heightened ability to invade or exit the<br>358 human host. In th Frotect against a limited number of the most invalid certain protection into certain virtues, less invasive, non-vaccine serotypes may exhibit heightened ability to invade or exit the human host. In this occasion, viral va  $358$  human host. In this occasion, viral vaccines, may further contribute to the reduction of the serotypes or exist to invade or exist the series of 358 human host. In this occasion, viral vaccines, may further contribute to the reduction of

359 pneumococcal disease burden and onwards transmission as an additional benefit beyond the virus-

361 Acknowledgments<br>362 We thank all the patients<br>363 clinical staff who helped<br>364 supported by the Bill and

364 supported by the Bill and Melinda Gates Foundation (grant no. OPP1117728) and the UK Medical

362 We thank all the pa<br>363 clinical staff who<br>364 supported by the B<br>365 Research Council ( 363 clinical staff who helped with recruitment and sample collection. The study was financially<br>364 supported by the Bill and Melinda Gates Foundation (grant no. OPP1117728) and the UK Medical<br>365 Research Council (grant n supported by the Bill and Melinda Gates Foundation (grant no. OPP1117728) and the UK Medical<br>Research Council (grant no. M011569/1) awarded to D.M.F and S.B.G. and a Robert Austrian<br>Research award awarded to E.M.<br>**Authors** 365 Research Council (grant no. M011569/1) awarded to D.M.F and S.B.G. and a Robert Austrian<br>366 Research award awarded to E.M.<br>367 Authors Contribution (E.M. M.H., A.H.W., M.F., R.R and A.M.C. recruited,

Research award awarded to E.M.<br>365 Research award awarded to E.M.<br>363 E.M and D.M.F conceived and designed the study. H.H, A.H.W., M.F., R.R and A.M.C. recruited,<br>369 consented study participants and obtained human samples 367 Authors Contribution<br>368 E.M and D.M.F conceived and d<br>369 consented study participants and<br>370 samples. E.M, E.N., A.G, J.R and D 368 E.M and D.M.F conce<br>369 consented study partic<br>370 samples. E.M, E.N., A.C<br>371 E.M., A.G. and D.M.F i

369 consented study participants and obtained human samples. E.N, A.B, A.H, J.R, F.E and C.S processed<br>370 samples. E.M, E.N., A.G, J.R and D.B generated and analysed the data.<br>371 E.M., A.G. and D.M.F interpreted data. E.

- 
- 370 samples. E.M, E.N., A.G, J.R and D.B generated and analysed the data.<br>371 E.M., A.G. and D.M.F interpreted data. E.M. wrote the manuscript and with subsequent inputs from<br>372 the co-authors. All co-authors approved the E.M., A.G. and D.M.F interpreted data. E.M. wrote the manuscript and<br>372 the co-authors. All co-authors approved the final version of the manus<br>373<br>374
- 372 the co-authors. All co-authors approved the final version of the manuscript.<br>373<br>374<br>375 References
- 
- 

373<br>373<br>374 **References**<br>376 1. Almeida ST, Paulo AC, Froes F, de Lencastre H, Sa-Leao R. Dynamics ---<br>374<br>375<br>376<br>377 375<br>376<br>377<br>378<br>379<br>380

375 References<br>376 1. Alm<br>377 Carriage in /<br>378 2020/09/03<br>379 2. Smi<br>380 colonisation<br>381 prevalence a<br>382 Epub 2020/ 377 Carriage in Adults: A New Look at an Old Paradigm. J Infect Dis. 2021;223(9):1590-600. Epub<br>378 2020/09/03. doi: 10.1093/infdis/jiaa558. PubMed PMID: 32877517.<br>379 2. Smith EL, Wheeler I, Adler H, Ferreira DM, Sa-Leao 2020/09/03. doi: 10.1093/infdis/jiaa558. PubMed PMID: 32877517.<br>
2. Smith EL, Wheeler I, Adler H, Ferreira DM, Sa-Leao R, Abdullahi O, et al. Upper airway<br>
colonisation of Streptococcus pneumoniae in adults aged 60 years a 2. Smith EL, Wheeler I, Adler H, Ferreira DM, Sa-Leao R, Abdull:<br>
380 colonisation of Streptococcus pneumoniae in adults aged 60 years are<br>
381 prevalence and individual participant data meta-analysis of risk fact<br>
382 Epu colonisation of Streptococcus pneumoniae in adults aged 60 years and older: A systematic reviction prevalence and individual participant data meta-analysis of risk factors. J Infect. 2020;81(4):540<br>
Epub 2020/06/21. doi: 1

931 prevalence and individual participant data meta-analysis of risk factors. J Infect. 2020;81(4):540-8.<br>
382 Epub 2020/06/21. doi: 10.1016/j.jinf.2020.06.028. PubMed PMID: 32562794; PubMed Central<br>
383 PMCID: PMCPMC75327 5382 Epub 2020/06/21. doi: 10.1016/j. jinf.2020.06.028. PubMed PMID: 32562794; PubMed Central<br>
383 PMCID: PMCPMC7532703.<br>
384 3. Regev-Yochay G, Raz M, Dagan R, Porat N, Shainberg B, Pinco E, et al. Nasopharyngeal<br>
385 Car 283 PMCID: PMCPMC7532703.<br>
383 PMCID: PMCPMC7532703.<br>
384 3. Regev-Yochay G, Raz M, Dagan R, Porat N, Shainberg B, Pinco E, et al. Nasopharyngeal<br>
385 Carriage of Streptococcus pneumoniae by Adults and Children in Communit 384 3. Regev-Yochay G, Ra<br>385 Carriage of Streptococcus p<br>386 Clinical Infectious Diseases.<br>387 4. Adegbola RA, DeAn<br>388 pneumoniae and other resp<br>399 systematic review and meta<br>390 10.1371/journal.pone.0103<br>391 PMCPMC4118

Carriage of Streptococcus pneumoniae by Adults and Children in Community and Family Settin<br>
286 Clinical Infectious Diseases. 2004;38(5):632-9. doi: 10.1086/381547.<br>
287 4. Adegbola RA, DeAntonio R, Hill PC, Roca A, Usuf E 386 Clinical Infectious Diseases. 2004;38(5):632-9. doi: 10.1086/381547.<br>387 4. Adegbola RA, DeAntonio R, Hill PC, Roca A, Usuf E, Hoet B, et al. Carriage of Streptococcus<br>388 pneumoniae and other respiratory bacterial pat 387 4. Adegbola RA, DeAntonio R, Hill PC, Roca A, Usuf E, Hoet B, et<br>388 pneumoniae and other respiratory bacterial pathogens in low and lo<br>389 systematic review and meta-analysis. PLoS One. 2014;9(8):e103293.<br>390 10.1371/ 388 pneumoniae and other respiratory bacterial pathogens in low and lower-middle income countries:<br>389 systematic review and meta-analysis. PLoS One. 2014;9(8):e103293. doi:<br>390 10.1371/journal.pone.0103293. PubMed PMID: 2 systematic review and meta-analysis. PLoS One. 2014;9(8):e103293. doi:<br>390 10.1371/journal.pone.0103293. PubMed PMID: 25084351; PubMed Central PMCID:<br>391 PMCPMC4118866.<br>392 5. Bogaert D, De Groot R, Hermans PW. Streptococc

380 10.1371/journal.pone.0103293. PubMed PMID: 25084351; PubMed Cent<br>391 PMCPMC4118866.<br>392 5. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae<br>393 pneumococcal disease. Lancet Infect Dis. 2004;4(3):144-54. doi:

- 391 PMCPMC4118866.<br>392 5. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisatio<br>393 pneumococcal disease. Lancet Infect Dis. 2004;4(3):144-54. doi: 10.1016/S1473-3099<br>2013 PubMed PMID: 14998500. 392 5. Bogaert D,<br>393 pneumococcal dises<br>394 PubMed PMID: 149 393 pneumococcal disease. Lancet Infect Dis. 2004;4(3):144-54. doi: 10.1016/S1473-3099(04)00938-7<br>394 PubMed PMID: 14998500.<br>PubMed PMID: 14998500.
- $394$  pubMed PMID: 14998500.<br>PubMed PMID: 14998500.

395 6.

396 and invasion. Nat Rev Microbiol. 2018;16(6):355-67. doi: 10.1038/s41579-018-0001-8. PubMed<br>397 PMID: 29599457; PubMed Central PMCID: PMCPMC5949087.<br>398 7. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL 937 PMID: 29599457; PubMed Central PMCID: PMCPMC5949087.<br>
398 7. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, et al. The fundamental<br>
399 between pneumococcal carriage and disease. Expert Rev Vaccines. 398 7. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O<br>399 between pneumococcal carriage and disease. Expert Rev Vacc<br>400 10.1586/erv.12.53. PubMed PMID: 22913260.<br>401 8. Danino D, Ben-Shimol S, van der Beek BA, Giv 398 7. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL, et al. The fundamental link<br>399 between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11(7):841-55. doi:<br>400 10.1586/erv.12.53. PubMed 399 10.1586/erv.12.53. PubMed PMID: 22913260.<br>
3. Danino D, Ben-Shimol S, van der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, et al.<br>
3. Danino D, Ben-Shimol S, van der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, et al.<br> 401 8. Danino D, Ben-Shimol S, van der Beek 402 in Pneumococcal Disease in Young Children Du<br>403 Pandemic in Israel Associated With Suppressio<br>404 Pneumococcal Carriage: A Prospective Cohort 1<br>405 2021/12/15. doi: 10.1093/ in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19)<br>
403 In Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19)<br>
403 Pandemic in Israel Associated With

Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Pers<br>
404 Pneumococcal Carriage: A Prospective Cohort Study. Clin Infect Dis. 2022;75(1):e1154-e64. E<sub>1</sub><br>
405 2021/12/15. doi: 10.1093 Preumococcal Carriage: A Prospective Cohort Study. Clin Infect Dis. 2022;75(1):e1154-e64. Epub<br>
405 2021/12/15. doi: 10.1093/cid/ciab1014. PubMed PMID: 34904635; PubMed Central PMCID:<br>
9. Rybak A, Levy C, Angoulvant F, Auv 2021/12/15. doi: 10.1093/cid/ciab1014. PubMed PMID: 34904635; PubMed Central PMCID:<br>
2021/12/15. doi: 10.1093/cid/ciab1014. PubMed PMID: 34904635; PubMed Central PMCID:<br>
2021 PMCPMC8754767.<br>
2021 PubMa A, Levy C, Angoulvan PMCPMC8754767.<br>
407 9. Rybak A, Levy C, Angoulvant F, Auvrignon A, Gembara P, Danis K, et al. Association of<br>
408 Nonpharmaceutical Interventions During the COVID-19 Pandemic With Invasive Pneumococc<br>
409 Disease, Pneumoco 407 9. Rybak A, Le<br>
408 Nonpharmaceutica<br>
409 Disease, Pneumoco<br>
410 Netw Open. 2022;5<br>
411 PubMed PMID: 357<br>
412 10. Weinberge<br>
413 respiratory syncytia<br>
414 hospitalization data Monpharmaceutical Interventions During the COVID-19 Pandemic With Invasive Pneumococca<br>
409 Disease, Pneumococcal Carriage, and Respiratory Viral Infections Among Children in France. J.<br>
410 Netw Open. 2022;5(6):e2218959.

Disease, Pneumococcal Carriage, and Respiratory Viral Infections Among Children in France. JAI<br>
1410 Netw Open. 2022;5(6):e2218959. Epub 2022/06/29. doi: 10.1001/jamanetworkopen.2022.1899<br>
1411 PubMed PMID: 35763298; PubMe Metw Open. 2022;5(6):e2218959. Epub 2022/06/29. doi: 10.1001/jamanetworkopen.2022.18959.<br>
411 Netw Open. 2022;5(6):e2218959. Epub 2022/06/29. doi: 10.1001/jamanetworkopen.2022.18959.<br>
412 UD. Weinberger DM, Klugman KP, Ste 411 PubMed PMID: 35763298; PubMed Central PMCID: PMCPMC9240903.<br>412 10. Weinberger DM, Klugman KP, Steiner CA, Simonsen L, Viboud C. Association between<br>413 respiratory syncytial virus activity and pneumococcal disease in

10. Weinberger DM, Klugman KP, Steiner CA, Simonsen L, Viboud C<br>143 respiratory syncytial virus activity and pneumococcal disease in infants:<br>144 hospitalization data. PLoS Med. 2015;12(1):e1001776. Epub 2015/01/0<br>10.1371/ experiency syncytial virus activity and pneumococcal disease in infants: a time series analysis (hospitalization data. PLoS Med. 2015;12(1):e1001776. Epub 2015/01/07. doi:<br>10. 1371/journal.pmed.1001776. PubMed PMID: 255623 414 hospitalization data. PLoS Med. 2015;12(1):e1001776. Epub 2015/01/07. doi:<br>415 10.1371/journal.pmed.1001776. PubMed PMID: 25562317; PubMed Central PMCID:<br>416 PMCPMC4285401.<br>417 11. Hernandez S, Munoz-Almagro C, Ciruela 415 10.1371/journal.pmed.1001776. PubMed PMID: 25562317; PubMed Central F<br>416 PMCPMC4285401.<br>417 11. Hernandez S, Munoz-Almagro C, Ciruela P, Soldevila N, Izquierdo C, Co<br>418 Invasive Pneumococcal Disease and Influenza Act MCPMC4285401.<br>
416 PMCPMC4285401.<br>
417 11. Hernandez S, Munoz-Almagro C, Ciruela P, Soldevila N, Izquierdo C, Codina M<br>
418 Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impa<br>
419 Vaccinat 417 11. Hernandez<br>
418 Invasive Pneumoco<br>
419 Vaccination in Pand<br>
420 2019/06/14. doi: 10<br>
421 PMCPMC6663900.<br>
422 12. Stark JM, St<br>
423 of mice following p<br>
424 10.1002/jmv.20631 Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV<br>
419 Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV<br>
419 Vaccination in Pandemic Vaccination in Pandemic and Nonpandemic Influenza Periods. J Clin Microbiol. 2019;57(8). Epub<br>
420 2019/06/14. doi: 10.1128/JCM.00363-19. PubMed PMID: 31189583; PubMed Central PMCID:<br>
421 PMCPMC6663900.<br>
422 12. Stark JM,

2019/06/14. doi: 10.1128/JCM.00363-19. PubMed PMID: 31189583; PubMed Central PMCID:<br>
21 PMCPMC6663900.<br>
422 12. Stark JM, Stark MA, Colasurdo GN, LeVine AM. Decreased bacterial clearance from the lu<br>
22 of mice following p PMCPMC6663900.<br>
422 12. Stark JM, Stark MA, Colasurdo GN, LeVine AM. Decreased bacterial clearance from the<br>
423 of mice following primary respiratory syncytial virus infection. J Med Virol. 2006;78(6):829-38.<br>
424 10.1002 422 12. Stark JM, St<br>
423 of mice following p<br>
424 10.1002/jmv.20631<br>
425 13. Smith CM, St<br>
426 syncytial virus incre<br>
427 protein 1a. A new p<br>
428 207. doi: 10.1164/r<br>
429 PMCPMC4226051 of mice following primary respiratory syncytial virus infection. J Med Virol. 2006;78(6):829-38. doi:<br>
10.1002/jmv.20631. PubMed PMID: 16628585.<br>
425 13. Smith CM, Sandrini S, Datta S, Freestone P, Shafeeq S, Radhakrishnan 10.1002/jmv.20631. PubMed PMID: 16628585.<br>
13. Smith CM, Sandrini S, Datta S, Freestone P, Shafeeq S, Radhakrishnan P, et al. Respiratory<br>
1426 syncytial virus increases the virulence of Streptococcus pneumoniae by binding 425 13. Smith CM, Sandrini S, Datta S, Freestone<br>426 syncytial virus increases the virulence of Strepto<br>427 protein 1a. A new paradigm in respiratory infect<br>428 207. doi: 10.1164/rccm.201311-21100C. PubMe<br>429 PMCPMC4226051 syncytial virus increases the virulence of Streptococcus pneumoniae by binding to penicillin bindin<br>protein 1a. A new paradigm in respiratory infection. Am J Respir Crit Care Med. 2014;190(2):196-<br>207. doi: 10.1164/rccm.20 protein 1a. A new paradigm in respiratory infection. Am J Respir Crit Care Med. 2014;190(2):196-<br>
207. doi: 10.1164/rccm.201311-21100C. PubMed PMID: 24941423; PubMed Central PMCID:<br>
PMCPMC4226051.<br>
14. Levine H, Zarka S, D

207. doi: 10.1164/rccm.201311-2110OC. PubMed PMID: 24941423; PubMed Central PMCID:<br>
429 PMCPMC4226051.<br>
430 14. Levine H, Zarka S, Dagan R, Sela T, Rozhavski V, Cohen DI, et al. Transmission of<br>
51 Streptococcus pneumoniae MCPMC4226051.<br>
429 PMCPMC4226051.<br>
430 14. Levine H, Zarka S, Dagan R, Sela T, Rozhavski V, Cohen DI, et al. Transmission of<br>
431 Streptococcus pneumoniae in adults may occur through saliva. Epidemiol Infect. 2012;140(3)<br> 430 14. Levine H, Z;<br>431 Streptococcus pneu<br>432 Epub 2011/06/17. c<br>433 15. Givon-Lavi<br>434 of Streptococcus pr<br>435 Epub 2003/06/12. c<br>436 16. Zangari T, C<br>437 Factor Driving Strep

431 Streptococcus pneumoniae in adults may occur through saliva. Epidemiol Infect. 2012;1<br>432 Epub 2011/06/17. doi: 10.1017/S0950268811000884. PubMed PMID: 21676361.<br>433 15. Givon-Lavi N, Fraser D, Dagan R. Vaccination of Epub 2011/06/17. doi: 10.1017/S0950268811000884. PubMed PMID: 21676361.<br>
15. Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees reduces carriage<br>
15. Givon-Lavi N, Fraser D, Dagan R. Vaccination of d 433 15. Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees<br>434 15. Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees<br>434 16 Streptococcus pneumoniae among their younger siblin 434 of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J. 2003;22(6):524-32.<br>435 Epub 2003/06/12. doi: 10.1097/01.inf.0000069760.65826.f2. PubMed PMID: 12799509.<br>436 16. Zangari T, Ortigoza MB, Lo Epub 2003/06/12. doi: 10.1097/01.inf.0000069760.65826.f2. PubMed PMID: 12799509.<br>
16. Zangari T, Ortigoza MB, Lokken-Toyli KL, Weiser JN. Type I Interferon Signaling Is a Common<br>
Factor Driving Streptococcus pneumoniae and 243 Central PMCID: PMCPMC3249639.<br>
435 Eactor Driving Streptococcus pneumoniae and Influenza A Virus Shedding and Transmissic 2021;12(1). Epub 2021/02/18. doi: 10.1128/mBio.03589-20. PubMed PMID: 33593970; P<br>
439 Central P

Factor Driving Streptococcus pneumoniae and Influenza A Virus Shedding and Transmission. mBio.<br>
438 2021;12(1). Epub 2021/02/18. doi: 10.1128/mBio.03589-20. PubMed PMID: 33593970; PubMed<br>
2021;12(1). Epub 2021/02/18. doi: 2021;12(1). Epub 2021/02/18. doi: 10.1128/mBio.03589-20. PubMed PMID: 33593970; PubMed<br>
449 Central PMCID: PMCPMC8545127.<br>
440 17. McCullers JA, McAuley JL, Browall S, Iverson AR, Boyd KL, Henriques Normark B. Influenza<br>
4 243 Central PMCID: PMCPMC8545127.<br>440 I7. McCullers JA, McAuley JL, Browall S, Iverson AR, Boyd KL, Henriques Normark B. Influenzi<br>441 enhances susceptibility to natural acquisition of and disease due to Streptococcus pneu 440 17. McCullers JA, McAuley JL, B<br>
441 enhances susceptibility to natural a<br>
442 ferrets. J Infect Dis. 2010;202(8):12<br>
443 Central PMCID: PMCPMC3249639. 441 enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in<br>1442 ferrets. J Infect Dis. 2010;202(8):1287-95. doi: 10.1086/656333. PubMed PMID: 20822454; PubMe<br>143 Central PMCID: PMC 442 ferrets. J Infect Dis. 2010;202(8):1287-95. doi: 10.1086/656333. PubMed PMID: 20822454; PubMe<br>443 Central PMCID: PMCPMC3249639.<br>.  $443$  Central PMCID: PMCPMC3249639.<br> $249639.$ 

444 18. facilitates Streptococcus pneumoniae transmission and disease. FASEB J. 2010;24(6):1789-98. Epub<br>2010/01/26. doi: 10.1096/fj.09-146779. PubMed PMID: 20097876.<br>19. Richard AL, Siegel SJ, Erikson J, Weiser JN. TLR2 signaling 2010/01/26. doi: 10.1096/fj.09-146779. PubMed PMID: 20097876.<br>
19. Richard AL, Siegel SJ, Erikson J, Weiser JN. TLR2 signaling decreases transmission of<br>
1448 Streptococcus pneumoniae by limiting bacterial shedding in an i 447 19. Richard AL, Siegel SJ, Erikson J, Weiser JN. TLR2 signaling de<br>448 Streptococcus pneumoniae by limiting bacterial shedding in an infa<br>449 model. PLoS Pathog. 2014;10(8):e1004339. Epub 2014/08/29. doi: 2<br>450 PubMed 448 Streptococcus pneumoniae by limiting bacterial shedding in an infant mouse Influenza A comodel. PLoS Pathog. 2014;10(8):e1004339. Epub 2014/08/29. doi: 10.1371/journal.ppat.10<br>449 model. PLoS Pathog. 2014;10(8):e100433 model. PLoS Pathog. 2014;10(8):e1004339. Epub 2014/08/29. doi: 10.1371/journal.ppat.1004339.<br>450 PubMed PMID: 25166617; PubMed Central PMCID: PMCPMC4148449.<br>451 20. Jochems SP, Marcon F, Carniel BF, Holloway M, Mitsi E, Sm PubMed PMID: 25166617; PubMed Central PMCID: PMCPMC4148449.<br>
20. Jochems SP, Marcon F, Carniel BF, Holloway M, Mitsi E, Smith E, et al. Inflammation induce<br>
by influenza virus impairs human innate immune control of pneumoc 20. Jochems SP, Marcon F, Carniel BF, Holloway M, Mitsi E, Smith E<br>
452 by influenza virus impairs human innate immune control of pneumococ<br>
2018;19(12):1299-308. doi: 10.1038/s41590-018-0231-y. PubMed PMII<br>
PMCID: PMCPMC6 by influenza virus impairs human innate immune control of pneumococcus. Nat Immunol.<br>
2018;19(12):1299-308. doi: 10.1038/s41590-018-0231-y. PubMed PMID: 30374129; PubMed Central<br>
PMCID: PMCPMC6241853.<br>
21. Thors V, Ch 2018;19(12):1299-308. doi: 10.1038/s41590-018-0231-y. PubMed PMID: 30374129; PubM<br>454 PMCID: PMCPMC6241853.<br>455 21. Thors V, Christensen H, Morales-Aza B, Vipond I, Muir P, Finn A. The Effects of Live<br>456 Attenuated Influe PMCID: PMCPMC6241853.<br>
21. Thors V, Christensen H, Morales-Aza B, Vipond I, Muir P, Finn A. The Effects of Live<br>
455 Attenuated Influenza Vaccine on Nasopharyngeal Bacteria in Healthy 2 to 4 Year Olds. A Ran 455 21. Thors V, Christense<br>456 Attenuated Influenza Vaccin<br>457 Controlled Trial. Am J Respi<br>458 10.1164/rccm.201510-2000<br>469 PMCPMC4910891.<br>460 22. Rodrigues F, Foster<br>461 rhinitis symptoms, respirate<br>462 pneumoniae, Haem 465 21. Attenuated Influenza Vaccine on Nasopharyngeal Bacteria in Healthy 2 to 4 Year Olds. A Ra<br>457 Controlled Trial. Am J Respir Crit Care Med. 2016;193(12):1401-9. Epub 2016/01/08. doi:<br>458 10.1164/rccm.201510-20000C. Controlled Trial. Am J Respir Crit Care Med. 2016;193(12):1401-9. Epub 2016/01/08. doi:<br>10.1164/rccm.201510-20000C. PubMed PMID: 26742001; PubMed Central PMCID:<br>1459 PMCPMC4910891.<br>22. Rodrigues F, Foster D, Nicoli E, Trot 10.1164/rccm.201510-20000C. PubMed PMID: 26742001; PubMed Central PMCID:<br>
1459 PMCPMC4910891.<br>
22. Rodrigues F, Foster D, Nicoli E, Trotter C, Vipond B, Muir P, et al. Relationships be<br>
1461 rhinitis symptoms, respiratory MCPMC4910891.<br>
460 22. Rodrigues F, Foster D, Nicoli E, Trotter C, Vipond B, Muir P, et al. Relationshi<br>
1461 rhinitis symptoms, respiratory viral infections and nasopharyngeal colonization with<br>
1462 pneumoniae, Haemophil 460 22. Rodrigues F<br>
461 rhinitis symptoms, 1<br>
462 pneumoniae, Haem<br>
463 Pediatr Infect Dis J.<br>
464 23558321.<br>
465 23. Gritzfeld JF,<br>
466 Experimental huma<br>
467 PMID: 23439027; P 161 Thinitis symptoms, respiratory viral infections and nasopharyngeal colonization with Streptococc<br>
162 pneumoniae, Haemophilus influenzae and Staphylococcus aureus in children attending daycare.<br>
163 Pediatr Infect Dis 962 pneumoniae, Haemophilus influenzae and Staphylococcus aureus in children attending daycare.<br>
463 Pediatr Infect Dis J. 2013;32(3):227-32. doi: 10.1097/INF.0b013e31827687fc. PubMed PMID:<br>
23558321.<br>
23. Gritzfeld JF, Wr Pediatr Infect Dis J. 2013;32(3):227-32. doi: 10.1097/INF.0b013e31827687fc. PubMed PMID:<br>
23558321.<br>
23558321.<br>
465 23. Gritzfeld JF, Wright AD, Collins AM, Pennington SH, Wright AK, Kadioglu A, et al.<br>
466 Experimental hu 23558321.<br>
23. Gritzfeld JF, Wright AD, Collins AM, Pennington SH, Wright AK, Kadioglu A, et al.<br>
23. Gritzfeld JF, Wright AD, Collins AM, Pennington SH, Wright AK, Kadioglu A, et al.<br>
24. Collins AM, Wright AD, Mitsi E, G 465 23. Gri<br>466 Experiment<br>467 PMID: 2343<br>468 24. Col<br>469 Challenge 1<br>470 Respir Crit<br>471 25. Mit<br>472 Density Is Experimental human pneumococcal carriage. J Vis Exp. 2013; (72). doi: 10.3791/50115. P<br>
467 PMID: 23439027; PubMed Central PMCID: PMCPMC3601207.<br>
24. Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock CA, Pennington SH, Experimental PMCID: PMCPMC3601207.<br>
24. Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock CA, Pennington SH, et al. First Human Challenge Testing of a Pneumococcal Vaccine - Double Blind Randomised Controlled Trial. Am 24. Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock C.<br>
240 Challenge Testing of a Pneumococcal Vaccine - Double Blind R:<br>
25 Respir Crit Care Med. 2015. doi: 10.1164/rccm.201503-05420<br>
25. Mitsi E, Carniel B, Reine Challenge Testing of a Pneumococcal Vaccine - Double Blind Randomised Controlled Trial. Am J<br>
470 Respir Crit Care Med. 2015. doi: 10.1164/rccm.201503-05420C. PubMed PMID: 26114410.<br>
25. Mitsi E, Carniel B, Reine J, Rylanc Respir Crit Care Med. 2015. doi: 10.1164/rccm.201503-05420C. PubMed PMID: 26114410.<br>
25. Mitsi E, Carniel B, Reine J, Rylance J, Zaidi S, Soares-Schanoski A, et al. Nasal Pneumococ<br>
25. Mitsi E, Carniel B, Reine J, Rylance According Text Care Med. 2019/10/19. doi: 10.1164/rccm.201903-06070C. PubMed PMID: 31626559; PubMed Central Peditification of pheum 2019/10/19. doi: 10.1164/rccm.201903-06070C. PubMed PMID: 31626559; PubMed Central PMCPMC6 Density Is Associated with Microaspiration and Heightened Human Alveolar Macrophage<br>
473 Responsiveness to Bacterial Pathogens. Am J Respir Crit Care Med. 2020;201(3):335-47. Epub<br>
2019/10/19. doi: 10.1164/rccm.201903-0607 Responsiveness to Bacterial Pathogens. Am J Respir Crit Care Med. 2020;201(3):335-47. E<br>
474 2019/10/19. doi: 10.1164/rccm.201903-06070C. PubMed PMID: 31626559; PubMed Cen<br>
475 PMCPMC6999099.<br>
476 26. Tarrago D, Fenoll A, 2019/10/19. doi: 10.1164/rccm.201903-06070C. PubMed PMID: 31626559; PubMed Central P<br>2019/10/19. doi: 10.1164/rccm.201903-06070C. PubMed PMID: 31626559; PubMed Central P<br>26. Tarrago D, Fenoll A, Sanchez-Tatay D, Arroyo LA, PMCPMC6999099.<br>
26. Tarrago D, Fenoll A, Sanchez-Tatay D, Arroyo LA, Munoz-Almagro C, Esteva C, et al.<br>
1477 Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time<br>
218 PCR. Cl 476 26. Tarrago D, 1<br>477 Identification of pne<br>478 PCR. Clin Microbiol<br>479 PMID: 18844683.<br>480 27. Connor V, 6<br>481 transmission of <en<br>482 European Respirato<br>483 28. de Steenhu Identification of pneumococcal serotypes from culture-negative clinical specimens by novel<br>PCR. Clin Microbiol Infect. 2008;14(9):828-34. doi: 10.1111/j.1469-0691.2008.02028.x. Publ<br>PMID: 18844683.<br>27. Connor V, German E, eral specification of Cernal specification of Cernal specification of Cernal specification of Cernan E, Pojar S, Mitsi E, Hales C, Nikolaou E, et al. Hands are vehicles for<br>
1479 PCR. Clin Microbiol Infect. 2008;14(9):828-27. Connor V, German E. Pojar S, Mitsi E, Hales C, Nikolaou E, et al. Hands are vehicles for<br>27. Connor V, German E, Pojar S, Mitsi E, Hales C, Nikolaou E, et al. Hands are vehicles for<br>21. Connor V, German E, Pojar S, Mit 480 27. Connor V,<br>481 transmission of <e<br>482 European Respirat<br>483 28. de Steenh<br>484 Interaction betwe<br>485 influenza vaccine.<br>486 PMID: 31278315;<br>487 29. Jochems S transmission of <em>Streptococcus pneumoniae</em> in novel controlled human infection st<br>European Respiratory Journal. 2018;52(4):1800599. doi: 10.1183/13993003.00599-2018.<br>28. de Steenhuijsen Piters WAA, Jochems SP, Mitsi European Respiratory Journal. 2018;52(4):1800599. doi: 10.1183/13993003.00599-2018.<br>
28. de Steenhuijsen Piters WAA, Jochems SP, Mitsi E, Rylance J, Pojar S, Nikolaou E, et al.<br>
1484 Interaction between the nasal microbiot 28. de Steenhuijsen Piters WAA, Jochems SP, Mitsi E, Rylance J, Pojar S, Nikolaou E, etc.<br>484 Interaction between the nasal microbiota and S. pneumoniae in the context of live-attenu<br>485 influenza vaccine. Nat Commun. 2019 Interaction between the nasal microbiota and S. pneumoniae in the context of live-attenuated<br>
185 influenza vaccine. Nat Commun. 2019;10(1):2981. doi: 10.1038/s41467-019-10814-9. PubMed<br>
186 PMID: 31278315; PubMed Central influenza vaccine. Nat Commun. 2019;10(1):2981. doi: 10.1038/s41467-019-10814-9. PubMed<br>
1486 Influenza vaccine. Nat Commun. 2019;10(1):2981. doi: 10.1038/s41467-019-10814-9. PubMed<br>
1486 PMID: 31278315; PubMed Central PMC 2486 PMID: 31278315; PubMed Central PMCID: PMCPMC6611866.<br>
29. Jochems SP, Piddock K, Rylance J, Adler H, Carniel BF, Collins A, et al. Novel Analysis of<br>
1488 Immune Cells from Nasal Microbiopsy Demonstrates Reliable, Rep 29. Jochems SP, Piddock K, Rylance J, Adler H, Carniel BF, 488 Immune Cells from Nasal Microbiopsy Demonstrates Reliable,<br>2017;12(1):e0169805. doi: 10.1371/journal.pone.0169805. Pu<br>2017;12(1):e0169805. doi: 10.1371/journal France Collis from Nasal Microbiopsy Demonstrates Reliable, Reproducible Data for Immune<br>
1889 Immune Cells from Nasal Microbiopsy Demonstrates Reliable, Reproducible Data for Immune<br>
1899 Populations, and Superior Cytokin Populations, and Superior Cytokine Detection Compared to Nasal Wash. PLoS One.<br>
2017;12(1):e0169805. doi: 10.1371/journal.pone.0169805. PubMed PMID: 28107457; PubMed<br>
Central PMCID: PMCPMC5249128.<br>
30. Dobin A, Davis CA, S 2017;12(1):e0169805. doi: 10.1371/journal.pone.0169805. PubMed PMID: 281074!<br>491 Central PMCID: PMCPMC5249128.<br>492 30. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ult<br>81 RNA-seq aligner. Bio 491 Central PMCID: PMCPMC5249128.<br>492 30. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast univer<br>493 RNA-seq aligner. Bioinformatics. 2013;29(1):15-21. Epub 2012/10/30. doi:<br>RNA-seq al 492 30. Dobin A, Davis CA, Schlesin<br>193 RNA-seq aligner. Bioinformatics. 20<br>193 493 RNA-seq aligner. Bioinformatics. 2013;29(1):15-21. Epub 2012/10/30. doi:<br> $E = 2013$ ;29(1):15-21. Epub 2012/10/30. doi:

 $\frac{1}{2}$  RNA-seq aligner. Biominical  $\frac{1}{2}$  ,  $\frac$ 

494 PMCPMC3530905.<br>
496 31. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program<br>
497 sequence reads to genomic features. Bioinformatics. 2014;30(7):923-30. Epub 2013/<br>
498 10.1093/bioinformatics/btt656 496 31. Liao Y, Smy<br>497 sequence reads to 4<br>498 10.1093/bioinforma<br>499 32. Yates A, Ak<br>500 Nucleic Acids Res. 2<br>501 PMID: 26687719; P<br>502 33. Love MI, Hu<br>503 seq data with DESe sequence reads to genomic features. Bioinformatics. 2014;30(7):923-30. Epub 2013/11/15. doi:<br>
10.1093/bioinformatics/btt656. PubMed PMID: 24227677.<br>
32. Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, e 10.1093/bioinformatics/btt656. PubMed PMID: 24227677.<br>
10.1093/bioinformatics/btt656. PubMed PMID: 24227677.<br>
1499 S. Vates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et al. Ensembl 2016.<br>
16. Nucleic Ac 32. Yates A, Akanni W, Amode MR, Barrell D, Billis K, Ca<br>
500 Nucleic Acids Res. 2016;44(D1):D710-6. Epub 2015/12/22. c<br>
501 PMID: 26687719; PubMed Central PMCID: PMCPMC470283<br>
502 33. Love MI, Huber W, Anders S. Moderated Nucleic Acids Res. 2016;44(D1):D710-6. Epub 2015/12/22. doi: 10.1093/nar/gkv1157. PubMed<br>
1992. PubMed Central PMCID: PMCPMC4702834.<br>
1992. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for FORD PMID: 26687719; PubMed Central PMCID: PMCPMC4702834.<br>
502 Bed data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8. PubMed<br>
503 seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.118 33. Love MI, Huber W, Anders S. Moderated estimation of<br>503 seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.<br>504 PMID: 25516281; PubMed Central PMCID: PMCPMC4302049.<br>505 34. Subramanian A, Tamayo P, Mootha VK, PMID: 25516281; PubMed Central PMCID: PMCPMC4302049.<br>
505 34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set<br>
enrichment analysis: a knowledge-based approach for interpreting genome 34. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, I<br>506 enrichment analysis: a knowledge-based approach for interpre<br>507 Proc Natl Acad Sci U S A. 2005;102(43):15545-50. Epub 2005/1<br>708 PubMed PMID: 16199517; PubMed Cen enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profile<br>
For Natl Acad Sci U S A. 2005;102(43):15545-50. Epub 2005/10/04. doi: 10.1073/pnas.050658010<br>
PubMed PMID: 16199517; PubMed C 9507 Proc Natl Acad Sci U S A. 2005;102(43):15545-50. Epub 2005/10/04. doi: 10.1073/pnas.0506580102.<br>
508 PubMed PMID: 16199517; PubMed Central PMCID: PMCPMC1239896.<br>
35. Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov PubMed PMID: 16199517; PubMed Central PMCID: PMCPMC1239896.<br>
509 35. Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set<br>
enrichment analysis. bioRxiv. 2021:060012. doi: 10.1101/060012.<br>
3 35. Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Serg<br>
2010 35. Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Serg<br>
2021:060012. doi: 10.1101/060012.<br>
36. Jassal B, Matthews L, Viteri G, Gong C, Lorent enrichment analysis. bioRxiv. 2021:060012. doi: 10.1101/060012.<br>
511 36. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathwa<br>
knowledgebase. Nucleic Acids Research. 2019;48(D1):D498-D5 510 enrichment analysis. bioRxiv. 2021:060012. doi: 10.1101/060012.<br>511 36. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. The reactome pathway 36. Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat<br>512 knowledgebase. Nucleic Acids Research. 2019;48(D1):D498-D503.<br>513 37. Cheliotis KS, Jewell CP, Solorzano C, Urban B, Collins AM, N<br>514 season and environm 812 knowledgebase. Nucleic Acids Research. 2019;48(D1):D498-D503. doi: 10.1093/nar/gkz1031.<br>
513 37. Cheliotis KS, Jewell CP, Solorzano C, Urban B, Collins AM, Mitsi E, et al. Influence of sex,<br>
season and environmental ai 513 37. Cheliotis KS, Jewell CP, Solorzano C, Urban B, Collins AM, Mitsi E, et al. Influence of se<br>514 season and environmental air quality on experimental human pneumococcal carriage acquisit<br>515 retrospective cohort anal 514 season and environmental air quality on experimental human pneumococcal carriage acquisitio<br>515 retrospective cohort analysis. ERJ Open Res. 2022;8(2). Epub 2022/04/14. doi:<br>516 10.1183/23120541.00586-2021. PubMed PMID 515 retrospective cohort analysis. ERJ Open Res. 2022;8(2). Epub 2022/04/14. doi:<br>516 10.1183/23120541.00586-2021. PubMed PMID: 35415189; PubMed Central PMCID:<br>517 PMCPMC8995542 manuscript from K.S. Cheliotis (PhD student 10.1183/23120541.00586-2021. PubMed PMID: 35415189; PubMed Central PI<br>
PMCPMC8995542 manuscript from K.S. Cheliotis (PhD student writing; no payr<br>
directly) and D.M. Ferreira (unfunded collaborator); grants or contracts re MCPMC8995542 manuscript from K.S. Cheliotis (PhD student writing; no payments<br>518 directly) and D.M. Ferreira (unfunded collaborator); grants or contracts received from<br>519 and JUNIPER Consortia) EPSRC (Bayes4Health progra directly) and D.M. Ferreira (unfunded collaborator); grants or contracts received from MRC (D<br>519 and JUNIPER Consortia) EPSRC (Bayes4Health programme and COVID-19 stochastic modelling<br>520 NERC (COVID-19 wastewater monitor and JUNIPER Consortia) EPSRC (Bayes4Health programme and COVID-19 stochastic modelling grant<br>520 MERC (COVID-19 wastewater monitoring), The Dogs Trust (clinical disease surveillance grant), BBSR(<br>521 (EEID elimination of d MERC (COVID-19 wastewater monitoring), The Dogs Trust (clinical disease surveillance grant), BBSRC<br>
521 (EEID elimination of disease grant) and the Wellcome Trust (GEM software grant), outside the<br>
522 submitted work; and 621 (EEID elimination of disease grant) and the Wellcome Trust (GEM software grant), outside the<br>522 submitted work; and participation on the ONS Covid Infection Survey Advisory Board (unfunded) and<br>523 SPI-M-O Covid Model submitted work; and participation on the ONS Covid Infection Survey Advisory Board (unfunde<br>
SPI-M-O Covid Modelling Subcommittee (unfunded), outside the submitted work. B. Urban rep<br>
grants or contracts from EDCTP, Royal 522 submitted work; and participation on the ONS Covid Infection Survey Advisory Board (unfunded) and grants or contracts from EDCTP, Royal Society and Pfizer, outside the submitted work; and is an<br>Inner Board Member of the Irish Research Council. A.M. Collins reports receiving grants or contract:<br>from Sanofi, Pfizer and U S25 Inner Board Member of the Irish Research Council. A.M. Collins reports receiving grants or contract from Sanofi, Pfizer and Unilever, outside the submitted work; consulting fees received from Sanotiside the submitted w 526 from Sanofi, Pfizer and Unilever, outside the submitted work; consulting fees received from Sanofi,<br>527 outside the submitted work; payment or honoraria for lectures, presentations, speakers' bureaus,<br>528 manuscript wr outside the submitted work; payment or honoraria for lectures, presentations, speakers' bureaus,<br>528 manuscript writing or educational events received from Pfizer, GSK and MSD, outside the submitted<br>529 work; support for a outside the submitted work; payment or honoraria for lectures, presentations, speakers' bureaus,<br>528 manuscript writing or educational events received from Pfizer, GSK and MSD, outside the submitte<br>529 work; support for at work; support for attending meetings and/or travel received from GSK, outside the submitted work;<br>530 work; support for attending meetings and/or travel received from GSK, outside the submitted work;<br>531 the submitted work 530 and participation on a data safety monitoring or advisory board for Neisseria for S'ton UK, outside<br>531 the submitted work. E. Nikolaou reports grants or contracts from Sanofi, the LSTM and Wellcome<br>532 Trust Director' and participation on a data safety monitoring or advisory board for Neisseria for S'ton UK, outside<br>
the submitted work. E. Nikolaou reports grants or contracts from Sanofi, the LSTM and Wellcome<br>
Trust Director's catalyst Trust Director's catalyst fund, outside the submitted work. J. Rylance reports grants or contracts<br>
state of the submitted work, and participation on the "Preventing fees received from Sanofi, outside the submitted work; a Trust Director's catalyst fund, outside the submitted work. J. Rylance reports grants or contracts<br>
received from Wellcome Trust and NIHR, outside the submitted work; consulting fees received fr<br>
Sanofi, outside the submit Sandary br>
535 committee. D.M. Ferreira reports support for the present manuscript from MRC grant<br>
536 MR/M011569/1, and 535 committee. D.M. Ferreira reports support for the present manuscript from MRC grant<br>536 MR/M011569/1, and Bill and Melinda Gates Foundation OPP1117728; grants or contracts receiv-<br>537 from Pfizer, MSD and Sanofi, outsid MR/M011569/1, and Bill and Melinda Gates Foundation OPP1117728; grants or contra<br>
from Pfizer, MSD and Sanofi, outside the submitted work; and membership of the Hun<br>
Challenge Network for Vaccine Development and the BactiV 537 from Pfizer, MSD and Sanofi, outside the submitted work; and membership of the Human Infection<br>538 Challenge Network for Vaccine Development and the BactiVac network (Accelerating Bacterial<br>539 Vaccines). The remaining 538 Challenge Network for Vaccine Development and the BactiVac network (Accelerating Bacterial<br>
539 Challenge Network for Vaccine Development and the BactiVac network (Accelerating Bacterial<br>
540 38. Cilloniz C, Pericas JM Vaccines). The remaining authors have nothing to disclose.<br>
539 Vaccines). The remaining authors have nothing to disclose.<br>
540 38. Cilloniz C, Pericas JM, Rojas JR, Torres A. Severe Infections Due to Respiratory Viruses. 540 38. Cilloniz C, Pericas JM, Rojas JR, Torres A. Severe Infe<br>541 Respir Crit Care Med. 2022;43(1):60-74. Epub 2022/02/17.<br>542 PMID: 35172359.<br>543 39. Wolter N, Tempia S, Cohen C, Madhi SA, Venter M,<br>544 pneumococcal den 541 Respir Crit Care Med. 2022;43(1):60-74. Epub 2022/02/17. doi: 10.1055/s-0041-1740982. PubMed<br>542 PMID: 35172359.<br>543 39. Wolter N, Tempia S, Cohen C, Madhi SA, Venter M, Moyes J, et al. High nasopharyngeal<br>544 pneumoco 542 PMID: 35172359.<br>543 39. Wolter N, Tempia S, Cohen C, Madhi SA, Venter M, Moyes J, et al. High nasopharyngeal<br>544 pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal<br>1994 preum 543 39. Wolter N,<br>544 pneumococcal dei<br>2017

544 pheumococcal density, increased by viral coinfection, is associated with invasive pneumococcal<br>permococcal density, increased by viral coinfection, is associated with invasive pneumococcal  $\mathbf{1}_{\text{max}}$  preumococcal density, increased by viral coinfection, is associated with invasive preumococcal density, is associated with invasive preumococcal density in  $\mathbf{1}_{\text{max}}$ 

545 PubMed PMID: 24907383.<br>
547 40. Esposito S, Zampiero A, Terranova L, Ierardi V, Ascolese B, Daleno C, et al. Pneumococ<br>
548 bacterial load colonization as a marker of mixed infection in children with alveolar community<br>
55 547 40. Esposito S, Zampie<br>548 bacterial load colonization<br>549 acquired pneumonia and re<br>550 2013;32(11):1199-204. Epu<br>551 23743541. Siegel SJ, Roche AN<br>553 coinfection by providing ho<br>554 2014;16(1):55-67. Epub 20. 548 bacterial load colonization as a marker of mixed infection in children with alveolar community-<br>
549 bacterial load colonization as a marker of mixed infection in children with alveolar community-<br>
550 2013;32(11):1199 2013;32(11):1199-204. Epub 2013/06/08. doi: 10.1097/INF.0b013e31829ec274. PubMed PMID<br>551 23743541. Siegel SJ, Roche AM, Weiser JN. Influenza promotes pneumococcal growth during<br>552 41. Siegel SJ, Roche AM, Weiser JN. Infl 551 23743541.<br>551 23743541.<br>552 41. Siegel SJ, Roche AM, Weiser JN. Influenza promotes pneumococcal growth during<br>553 coinfection by providing host sialylated substrates as a nutrient source. Cell Host Microbe.<br>554 2014;16 552 41. Sie<br>
553 coinfection<br>
554 2014;16(1)<br>
555 PubMed Ce<br>
556 42. Tal<br>
557 of invasive<br>
558 syncytial vi<br>
559 10.1016/j.a coinfection by providing host sialylated substrates as a nutrient source. Cell Host Microbe.<br>
554 2014;16(1):55-67. Epub 2014/07/11. doi: 10.1016/j.chom.2014.06.005. PubMed PMID: 25<br>
71. PubMed Central PMCID: PMCPMC4096718 2014;16(1):55-67. Epub 2014/07/11. doi: 10.1016/j.chom.2014.06.005. PubMed PMID: 25<br>555 PubMed Central PMCID: PMCPMC4096718.<br>556 42. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, et al. Sea<br>557 of PubMed Central PMCID: PMCPMC4096718.<br>
556 42. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, et al. Seasonality<br>
557 of invasive pneumococcal disease: temporal relation to documented influenza and 42. Talbot TR, Poehling KA, Hartert TV, A<br>557 of invasive pneumococcal disease: temporal<br>558 syncytial viral circulation. Am J Med. 2005;1:<br>559 10.1016/j.amjmed.2004.09.016. PubMed PN<br>560 43. Rybak A, Levy C, Angoulvant F, 556 42. Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, et al. Seasonality<br>557 of invasive pneumococcal disease: temporal relation to documented influenza and respiratory 557 of invasive pneumococcal disease: temporal relation to documented influenza and respiratory<br>558 syncytial viral circulation. Am J Med. 2005;118(3):285-91. Epub 2005/03/05. doi:<br>559 10.1016/j.amjmed.2004.09.016. PubMed syncytial viral circulation. Am J Med. 2005;118(3):285-91. Epub 2005/03/05. doi:<br>
10.1016/j.amjmed.2004.09.016. PubMed PMID: 15745727.<br>
43. Rybak A, Levy C, Angoulvant F, Auvrignon A, Gembara P, Danis K, et al. Association 10.1016/j.amjmed.2004.09.016. PubMed PMID: 15745727.<br>
10.1016/j.amjmed.2004.09.016. PubMed PMID: 15745727.<br>
360 43. Rybak A, Levy C, Angoulvant F, Auvrignon A, Gembara P, Danis K, et al. As<br>
161 Nonpharmaceutical Intervent 13. Rybak A, Levy C, Angoulvant F, Auvrignon A, Gemba<br>
143. Rybak A, Levy C, Angoulvant F, Auvrignon A, Gemba<br>
1561 Nonpharmaceutical Interventions During the COVID-19 Pane<br>
1562 Disease, Pneumococcal Carriage, and Respira Monpharmaceutical Interventions During the COVID-19 Pandemic With Invasive Pneumococca<br>
Disease, Pneumococcal Carriage, and Respiratory Viral Infections Among Children in France. J.<br>
Network Open. 2022;5(6):e2218959-e. doi Disease, Pneumococcal Carriage, and Respiratory Viral Infections Among Children in France. JAI<br>
Network Open. 2022;5(6):e2218959-e. doi: 10.1001/jamanetworkopen.2022.18959.<br>
44. Madhi SA, Klugman KP, Vaccine Trialist G. A Network Open. 2022;5(6):e2218959-e. doi: 10.1001/jamanetworkopen.2022.18959.<br>564 44. Madhi SA, Klugman KP, Vaccine Trialist G. A role for Streptococcus pneumoniae in virus-<br>565 associated pneumonia. Nat Med. 2004;10(8):811 44. Madhi SA, Klugman KP, Vaccine Trialist G. A role for Streptococcus pneumonia<br>565 associated pneumonia. Nat Med. 2004;10(8):811-3. Epub 2004/07/13. doi: 10.1038/r<br>766 PubMed PMID: 15247911; PubMed Central PMCID: PMCPMC7 9566 PubMed PMID: 15247911; PubMed Central PMCID: PMCPMC7095883.<br>
567 45. Ghaffar F, Friedland IR, McCracken GH, Jr. Dynamics of nasopharyngeal colonization b<br>
568 Streptococcus pneumoniae. Pediatr Infect Dis J. 1999;18(7) 45. Ghaffar F, Friedland IR, McCracken GH, Jr. Dynamics of nasopha<br>568 Streptococcus pneumoniae. Pediatr Infect Dis J. 1999;18(7):638-46. doi<br>569 199907000-00016. PubMed PMID: 10440444.<br>570 46. Robinson J. Colonization and Streptococcus pneumoniae. Pediatr Infect Dis J. 1999;18(7):638-46. doi: 10.1097/00006454-<br>569 Streptococcus pneumoniae. Pediatr Infect Dis J. 1999;18(7):638-46. doi: 10.1097/00006454-<br>570 46. Robinson J. Colonization and i 199907000-00016. PubMed PMID: 10440444.<br>
570 46. Robinson J. Colonization and infection of the respiratory tract: What do we know? P.<br>
571 Child Health. 2004;9(1):21-4. doi: 10.1093/pch/9.1.21. PubMed PMID: 19654976; PubMe 9570 46. Robinson J. Colonization and infection<br>
571 Child Health. 2004;9(1):21-4. doi: 10.1093/pch<br>
572 PMCID: PMCPMC2719511.<br>
573 47. Greenberg D, Givon-Lavi N, Faingelern<br>
574 Nasopharyngeal Pneumococcal Carriage Durin<br> Child Health. 2004;9(1):21-4. doi: 10.1093/pch/9.1.21. PubMed PMID: 19654976; PubMed Central<br>
572 FMCID: PMCPMC2719511.<br>
47. Greenberg D, Givon-Lavi N, Faingelernt Y, Ben-Shimol S, Avni YS, Bar-Ziv J, et al.<br>
574 Nasophary For PMCID: PMCPMC2719511.<br>
572 PMCID: PMCPMC2719511.<br>
47. Greenberg D, Givon-Lavi N, Faingelernt Y, Ben-Shimol S, Avni YS, Bar-Ziv J, et al.<br>
1574 Nasopharyngeal Pneumococcal Carriage During Childhood Community-Acquired Al 572 PMCID: PMCPMC2719511.<br>573 47. Greenberg D, Givon-Lavi N, Faingelernt Y, Ben-Shimol S, Avni YS, Bar-Ziv J, et al. 573 47. Greenberg D, Givor<br>574 Nasopharyngeal Pneumoco<br>575 Pneumonia: Relationship Be<br>576 2017;215(7):1111-6. Epub 2<br>577 48. van Benten I, Koopi<br>578 Predominance of rhinovirus<br>579 Immunol. 2003;14(5):363-7<br>580 PMID: 146416 Nasopharyngeal Pneumococcal Carriage During Childhood Community-Acquired Alveola<br>
575 Pneumonia: Relationship Between Specific Serotypes and Coinfecting Viruses. J Infect Di<br>
576 2017;215(7):1111-6. Epub 2016/12/25. doi: 1 Frame Pharynes (Sending Detween Specific Serotypes and Coinfecting Viruses. J Infect Dis.<br>
575 Pneumonia: Relationship Between Specific Serotypes and Coinfecting Viruses. J Infect Dis.<br>
576 2017;215(7):1111-6. Epub 2016/12 2017;215(7):1111-6. Epub 2016/12/25. doi: 10.1093/infdis/jiw613. PubMed PMID: 280119<br>577 48. van Benten I, Koopman L, Niesters B, Hop W, van Middelkoop B, de Waal L, et al.<br>758 Predominance of rhinovirus in the nose of sym 48. van Benten I, Koopman L, Niesters B, Hop W, van Middelkoop B, de Waal L, et al.<br>578 Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatr Alle<br>579 Immunol. 2003;14(5):363-70. Epub 2003 577 48. van Benten I, Koopman L, Niesters B, Hop W, van Middelkoop B, de Waal L, et al. 579 Immunol. 2003;14(5):363-70. Epub 2003/12/04. doi: 10.1034/j.1399-3038.2003.00064.x. PubMed<br>580 PMID: 14641606; PubMed Central PMCID: PMCPMC7168036.<br>581 49. Zafar MA, Wang Y, Hamaguchi S, Weiser JN. Host-to-Host Transmi 580 PMID: 14641606; PubMed Central PMCID: PMCPMC7168036.<br>
5781 PMID: 14641606; PubMed Central PMCID: PMCPMC7168036.<br>
581 2587 Deumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. Cell Host Microbe. 2017;21(1):73-8.<br> 49. Zafar MA, Wang Y, Hamaguchi S, Weiser JN. Host-to-H<br>582 pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin<br>583 doi: 10.1016/j.chom.2016.12.005. PubMed PMID: 28081446; PMCPMC5267320.<br>585 50. Carniel BF, Marcon 982 pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. Cell Host Microbe. 2017;21(1):73-<br>
583 doi: 10.1016/j.chom.2016.12.005. PubMed PMID: 28081446; PubMed Central PMCID:<br>
9584 PMCPMC5267320.<br>
585 50. Carniel BF 583 doi: 10.1016/j.chom.2016.12.005. PubMed PMID: 28081446; PubMed Central PMCID:<br>584 PMCPMC5267320.<br>585 S0. Carniel BF, Marcon F, Rylance J, German EL, Zaidi S, Reine J, et al. Pneumococcal colonization<br>586 impairs mucosa 584 PMCPMC5267320.<br>585 50. Carniel BF, Marcon F, Rylance J, German EL, Zaidi S, Reine J, et al. Pneumococc<br>586 impairs mucosal immune responses to live attenuated influenza vaccine. JCI Insight. 20<br>587 2021/01/27. doi: 10. 585 50. Carniel BF,<br>
586 impairs mucosal im<br>
587 2021/01/27. doi: 10<br>
588 PMCPMC7934923.<br>
589 51. Weinberge<br>
590 Seasonal drivers of<br>
591 Clin Infect Dis. 2014<br>
592 Central PMCID: PM 586 impairs mucosal immune responses to live attenuated influenza vaccine. JCI Insight. 2021;6(4). Epub<br>587 2021/01/27. doi: 10.1172/jci.insight.141088. PubMed PMID: 33497364; PubMed Central PMCID:<br>588 PMCPMC7934923.<br>51. W 2021/01/27. doi: 10.1172/jci.insight.141088. PubMed PMID: 33497364; PubMed Central PMCID:<br>588 PMCPMC7934923.<br>589 51. Weinberger DM, Grant LR, Steiner CA, Weatherholtz R, Santosham M, Viboud C, et al.<br>590 Seasonal drivers o 588 PMCPMC7934923.<br>
589 51. Weinberger DM, Grant LR, Steiner CA, Weatherholtz R, Santosham M, Viboud C, et al.<br>
590 Seasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral activity<br>
591 C 589 51. Weinberge<br>
589 51. Weinberge<br>
590 Seasonal drivers of<br>
591 Clin Infect Dis. 2014<br>
592 Central PMCID: PM<br>
593 52. Dagan R, va<br>
594 al. The COVID-19 pa<br>
595 respiratory viruses Seasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral acti<br>
591. Clin Infect Dis. 2014;58(2):188-94. doi: 10.1093/cid/cit721. PubMed PMID: 24190895; PubMed<br>
592. Central PMCID: PMCPMC38 591 Clin Infect Dis. 2014;58(2):188-94. doi: 10.1093/cid/cit721. PubMed PMID: 24190895; PubMed<br>592 Central PMCID: PMCPMC3871795.<br>593 52. Dagan R, van der Beek BA, Ben-Shimol S, Greenberg D, Shemer-Avni Y, Weinberger DM, et 592 Central PMCID: PMCPMC3871795.<br>593 52. Dagan R, van der Beek BA, Ben-Shimol S, Greenberg D, Shemer-Avni Y, Weinberger DM,<br>194 al. The COVID-19 pandemic as an opportunity for unravelling the causative association betweer 593 52. Dagan R, van der Beek BA,<br>594 al. The COVID-19 pandemic as an o<br>595 respiratory viruses and pneumococ<br>795 594 al. The COVID-19 pandemic as an opportunity for unravelling the causative association between<br>
respiratory viruses and pneumococcus-associated disease in young children: a prospective study.<br>
The respiratory viruses an For the COVID-19 pandemic as an opportunity for unravelating the causative associations of the causative study<br>respiratory viruses and pneumococcus-associated disease in young children: a prospective study<br>control of the c

595 respiratory viruses and pneumococcus-associated disease in young children: a prospective study.

596 937 PMID: 36857965; PubMed Central PMCID: PMCPMC9970381.<br>
598 S. de Koff EM, van Houten MA, Sanders EAM, Bogaert D. Severity of Respiratory Infections<br>
599 With Seasonal Coronavirus Is Associated With Viral and Bacterial C 598 53. de Koff EM, van Houten MA, Sanders EAM, Bogaert D.<br>599 With Seasonal Coronavirus Is Associated With Viral and Bacter<br>600 2021;40(1):e36-e9. Epub 2020/10/13. doi: 10.1097/INF.00000<br>601 33044434. Lewnard JA, Bruxvoor With Seasonal Coronavirus Is Associated With Viral and Bacterial Coinfections. Pediatr Infect Dis<br>
2021;40(1):e36-e9. Epub 2020/10/13. doi: 10.1097/INF.0000000000002940. PubMed PMID:<br>
33044434. Lewnard JA, Bruxvoort KJ, Fi 2021;40(1):e36-e9. Epub 2020/10/13. doi: 10.1097/INF.0000000000002940. PubMed PMID:<br>
33044434. Lewnard JA, Bruxvoort KJ, Fischer H, Hong VX, Grant LR, Jodar L, et al. Prevention of COVID<br>
19 among older adults receiving pn 33044434.<br>
602 54. Lewnard JA, Bruxvoort KJ, Fischer H, Hong VX, Grant LR, Jodar L, et al. Prevention of C<br>
19 among older adults receiving pneumococcal conjugate vaccine suggests interactions betw<br>
503 19 among older adul 602 54. Lev<br>
603 19 among c<br>
604 Streptococc<br>
605 2021/03/12<br>
606 PMCPMC7<br>
607 55. Dav<br>
608 on nasopha<br>
608 indirect eff Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract. J Infect Dis. 2021. Epub<br>
2021/03/12. doi: 10.1093/infdis/jiab128. PubMed PMID: 33693636; PubMed Central PMCID:<br>
PMCPMC7989304.<br>
55. Davis SM, Deloria-Knoll 2021/03/12. doi: 10.1093/infdis/jiab128. PubMed PMID: 33693636; PubMed Central PMCID<br>
606 PMCPMC7989304.<br>
55. Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate<br>
608 on nasopharyngeal carriag PMCPMC7989304.<br>
607 55. Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate v<br>
608 on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evide<br>
indirect effects. 607 55. Davis SM, D<br>608 on nasopharyngeal<br>609 indirect effects. Vac<br>610 PubMed PMID: 236<br>611 56. German EL,<br>612 vaccine against exp<br>613 colonisation density<br>614 10.1016/j.vaccine.2 55. Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines<br>608 on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on<br>609 indirect effects. Vacc indirect effects. Vaccine. 2013;32(1):133-45. Epub 2013/05/21. doi: 10.1016/j.vaccine.2013.05.005.<br>610 PubMed PMID: 23684824.<br>611 56. German EL, Solorzano C, Sunny S, Dunne F, Gritzfeld JF, Mitsi E, et al. Protective effec Fig. 2010<br>610 PubMed PMID: 23684824.<br>611 56. German EL, Solorzano C, Sunny S, Dunne F, Gritzfeld JF, Mitsi E, et al. Protective effect of PC<br>612 vaccine against experimental pneumococcal challenge in adults is primarily me 610 PubMed PMID: 23684824.<br>611 56. German EL, Solorzano C, Sunny S, Dunne F, Gritzfeld JF, Mitsi E, et al. Protective effect of PCV 611 56. German EL, Solorza<br>612 vaccine against experiment<br>613 colonisation density. Vaccin<br>614 10.1016/j.vaccine.2019.05.<br>615 PMCPMC6611220. 912 vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling<br>613 colonisation density. Vaccine. 2019;37(30):3953-6. Epub 2019/06/10. doi:<br>10.1016/j.vaccine.2019.05.080. PubMed PMID

613 colonisation density. Vaccine. 2019;37(30):3953-6. Epub 2019/06/10. doi:<br>614 10.1016/j.vaccine.2019.05.080. PubMed PMID: 31176540; PubMed Central PMCID:<br>615 PMCPMC6611220.<br>7. Line 20 - Controlling of the controlling o 614 colonisation density. Vaccine. 2019. 05.080. PubMed PMID: 31176540; PubMed Centra<br>615 em MCPMC6611220.<br>Table 1: Characteristics of study participants





 $\overline{a}$ 



Figure 1. Presence of asymptomatic upper airway viral infection influences pneumococcal carriage<br>acquisition and bacterial density. A) Percentages of respiratory viruses detected in the upper acquisition and bacterial density. A) Percentages of respiratory viruses detected in the upper<br>airways of 581 healthy adults at baseline (prior to pneumococcal challenge). Differential distribution<br>of respiratory viruses d of respiratory viruses detected in those who did not become colonised (n=290, Spn- group) and<br>those who became colonised (n=291, Spn+ group). **B)** Percentages of pneumococcal colonisation<br>achieved after experimental chall those who became colonised (n=291, Spn+ group). **B)** Percentages of pneumococcal colonisation<br>achieved after experimental challenge in the virus negative (n=482) and virus-positive group (n=99).<br>**C)** Percentages of experi those who became colonised (n=291, Spn+ group). B) Percentages of pheumococcal colonisation<br>achieved after experimental challenge in the virus negative (n=482) and virus-positive group (n=99).<br>C) Percentages of experiment and Precentages of experimental pneumococcal colonisation achieved after challenge in those with<br>primary asymptomatic seasonal coronavirus (HCoV) infection (11 Spn+ out of 25, p=0.55), rhinovirus<br>(RH) infection (29 Spn+ ou primary asymptomatic seasonal coronavirus (HCoV) infection (11 Spn+ out of 25, p=0.55), rhinovirus (RH) infection (29 Spn+ out of 44, p=0.035), parainfluenza virus (HPIVs) infection (5 Spn+ out of 7,  $\left(RH\right)$ ) infection (RH) infection (29 Spn+ out of 44, p=0.035), parainfluenza virus (HPIVs) infection (5 Spn+ out of 7, p=0.55), rhinovirus (HPIVs) infection (5 Spn+ out of 7, (RH) infection (29 Spn+ out of 44, p=0.035), parameterization (i.e.  $p$ , and the  $p$  -spn+ out of 7,  $p$ 

p=0.25) and respiratory syncytiar virus (RSV) infection (7 Spn+ out of 8, p=0.034). D-0) Density<br>dynamics after pneumococcal inoculation were calculated from classical microbiology (log10[cfu/ml<br>+1]). D) Area under the cu 41]). **D)** Area under the curve (AUC) of density per time interval from day2 to day14 post inoculation with Spn6B in virus negative (n=208) and virus positive (n=43) individuals. **E-G)** Mean  $\pm$  SEM of pneumococcal densi with Spn6B in virus negative (n=208) and virus positive (n=43) individuals. **E-G)** Mean ± SEM of pneumococcal density in colonised individuals for each time point after inoculation in those who had primary asymptomatic vi meumococcal density in colonised individuals for each time point after inoculation in those who had<br>primary asymptomatic viral infection with seasonal coronavirus (HCoV, red) or rhinovirus (RH, green)<br>or RSV (purple) or n primary asymptomatic viral infection with seasonal coronavirus (HCoV, red) or rhinovirus (RH, green)<br>or RSV (purple) or no viral infection (Virus neg, grey). Statistical analysis was determined by Fisher's<br>exact test to c

primary (purple) or no viral infection (Virus neg, grey). Statistical analysis was determined by Fisher's exact test to compare percentages (D-E) or Mann-Whitney test (F,H & I) or Kruskal-Wallis test following correction exact test to compare percentages (D-E) or Mann-Whitney test (F,H & I) or Kruskal-Wallis test<br>following correction for multiple comparisons (G).  $p < 0.05$ , \*\*p < 0.01.<br>Figure 2. Inflammatory profile of the human upper air Following correction for multiple comparisons (G).  $p < 0.05$ ,  $*p < 0.01$ .<br>
Figure 2. Inflammatory profile of the human upper airway during asymptomatic URTI. A) Volcano<br>
plots and B) heatmap showing the median log<sub>2</sub> fold Figure 2. Inflammatory profile of the human upper airway during asy<br>plots and B) heatmap showing the median  $log_2$  fold change (FC) in the<br>nasal wash collected at baseline from individuals with HCoV (n = 20).<br>infection (n Figure 2. Inflammatory profile of the human upper antway during asymptomatic offit. A) volcano<br>plots and B) heatmap showing the median  $log_2$  fold change (FC) in the levels of 33 cytokines in the<br>nasal wash collected at ba plots and B) heatmap showing the median log<sub>2</sub> fold change (FC) in the levels of 33 cytokines in the<br>nasal wash collected at baseline from individuals with HCoV (n = 20), rhinovirus (n = 25) and RSV<br>infection (n = 8) versu infection (n = 8) versus non-viral infected group (n = 20). On volcano plots the horizontal dotted line<br>represents the cutoff of significance (adjusted p= 0.05, after False Discovery Rate correction of<br>the p value), where represents the cutoff of significance (adjusted p= 0.05, after False Discovery Rate correction of<br>the p value), whereas the vertical dotted line represents a cutoff point for determining whether the<br>levels of cytokines we the p value), whereas the vertical dotted line represents a cutoff point for determining whether the levels of cytokines were higher (right, red) or lower (left, blue) compared with those of non-viral infected group. Stat the p values) of cytokines were higher (right, red) or lower (left, blue) compared with those of non-viral<br>infected group. Statistical comparisons were applied between each study group and the virus<br>negative group using t infected group. Statistical comparisons were applied between each study group and the virus<br>negative group using the Mann-Whitney U test, followed by Benjamini-Hochberg correction for<br>multiple testing.  $p < 0.05$ ,  $**p < 0.0$ infective group using the Mann-Whitney U test, followed by Benjamini-Hochberg correction for<br>multiple testing.  $p < 0.05$ ,  $*^*p < 0.01$ ,  $**^*p < 0.001$ . Nonsignif, nonsignificant; Down,<br>downregulation; Up, upregulation.<br>Fig

multiple testing.  $p < 0.05$ ,  $*^{*}p < 0.01$ ,  $*^{*}p < 0.001$ . Nonsignif, nonsignificant; Down,<br>downregulation; Up, upregulation.<br>Figure 3. Route of bacterial shedding and association with colonising density. A) Percentage o multiple testing. Up, upregulation.<br>
Figure 3. Route of bacterial shedding and association with colonising density. A) Percentage of<br>
bacterial shedders (n=47) and non-shedders (n=74) amongst the Spn colonised individuals Figure 3. Route of bacterial shed<br>bacterial shedders (n=47) and non-<br>breakdown for route of shedding<br>density per time point after inocu<br>through the nose (nose-shedders, r Figure 3. Roace of bacterial shedding and association with colonising density. A) Percentage of bacterial shedders (n=47) and non-shedders (n=74) amongst the Spn colonised individuals (top) and breakdown for route of shed breakdown for route of shedding in the Spn shedders. **B)** Mean ± SEM of nasal pneumococcal<br>density per time point after inoculation day (D0) in Spn colonised individuals who shed bacteria<br>through the nose (nose-shedders, n breakdown for foute of shedding in the Spin shedders. B) Wealt 1 SEM of hasal phealifococcal<br>density per time point after inoculation day (D0) in Spn colonised individuals who shed bacteria<br>through the nose (nose-shedders, density per time point after increasing to pyramical material material through the nose (nose-shedders, n=30) or mouth while coughing (cough-shedders, n=15) or did not shed bacterial (non-shedders, n=74). C) Incidence of b through three intentions, nearly the normal time conging (conginatellity, nearly in the nose-<br>shedders in association with nasal pneumococcal density expressed as log10 increased increments.<br>D) Correlation between nasal Sp shedders in association with nasal pneumococcal density expressed as log10 increased increments.<br> **D)** Correlation between nasal Spn density (CFU/ml of NW) and shedding density (CFU/ml), Linear<br>
regression line with 95% co **D)** Correlation between nasal Spn density (CFU/ml of NW) and shedding density (CFU/ml), Linear regression line with 95% confidence interval (grey shading) are shown. **E)** Percentage of Spn-<br>shedders who emitted bacterial **D)** Correlation between masal Spir density (CFO/mF of NW) and shedding density (CFO/mF), Enter<br>regression line with 95% confidence interval (grey shading) are shown. **E**) Percentage of Spn-<br>shedders who emitted bacterial regression line with 95% confidence interval (grey shading) are shown. L<sub>J</sub> referringe of Spin-<br>shedders who emitted bacterial via coughing or nose per each time point after spn challenge. F)<br>Levels of nasal pneumococcal d shedders who emitted bacterial via coughing or nose per each time point after spir challenge. T)<br>Levels of nasal pneumococcal density measured per time point Pl in cough-shedders (turquoise) and<br>nose-shedders (purple). Dat Levels of nasal production and provide per time percentation origination process the density. G)<br>
Respiratory viral infection incidence in non-shedders, nose- and cough-shedders. Statistical<br>
differences were determined by nose shedders (purple). Data are presented as median values and interquartile ranges (iQRs). G)<br>Respiratory viral infection incidence in non-shedders, nose- and cough-shedders. Statistical<br>differences were determined by Kr

Respiratory viral inferred in non-shedler Wallis test following correction for multiple comparisons<br>(B), Fisher-test exact test (C) or two-tailed Spearman rank test (D).  $***$   $p < 0.001$ ,  $***$   $p < 0.0001$ .<br>Figure 4. Distinct (B), Fisher-test exact test (C) or two-tailed Spearman rank test (D). \*\*\*\*p < 0.001, \*\*\*\*p < 0.0001.<br>
Figure 4. Distinct nasal inflammatory profile in those with asymptomatic URT infection. A) Volcano<br>
plots showing the m Figure 4. Distinct nasal inflammatory profile in those with asymptomatic URT infection. A) Volc<br>plots showing the median and IQR of nasal monocyte, neutrophils and T cell numbers normalised<br>the epithelial cell numbers in n - ト オ ミ c Figure 4. Distinct nasal inflammatory profile in those with asymptomatic OKF infection. A) volcano<br>plots showing the median and IQR of nasal monocyte, neutrophils and T cell numbers normalised to<br>the epithelial cell number plots showing and numbers in non-shedders (n=), cough-shedders (n=) and nose-shedders (n=).<br>Statistical differences were determined by Kruskal-Wallis test following correction for multiple<br>comparisons. B) Gene set variance Statistical differences were determined by Kruskal–Wallis test following correction for multiple<br>comparisons. B) Gene set variance analysis (GSVA) of immune response pathways of nasal cells<br>collected at D2, D6 and D16 afte Statistical differences were determined by Krama, Cambridge Contention for multiple-<br>comparisons. B) Gene set variance analysis (GSVA) of immune response pathways of nasal cells<br>collected at D2, D6 and D16 after pneumococc collected at D2, D6 and D16 after pneumococcal in cough- and nose-shedders in relation to non-<br>collected at D2, D6 and D16 after pneumococcal in cough- and nose-shedders in relation to nonpresented in gradient colour. Red shades indicate pathways overrepresented, whereas blue shades<br>depict the underrepresented pathways at each time point in relation to non-sheders group.<br>Statistical differences were determi presented in gradient colonial methods of the shades independent colonicatistical differences were determined by Wilcoxon's paired test corrected by multiple-comparison<br>testing (Benjamini-Hochberg).<br>Figure 5. Nasal inflamm

Statistical differences were determined by Wilcoxon's paired test corrected by multiple-comparison<br>testing (Benjamini-Hochberg).<br>Figure 5. Nasal inflammation in nose-shedders and correlation bacterial density and shedding. Statistical differences were determined by Statistical Controllect Comparison<br>Stating (Benjamini-Hochberg).<br>Figure 5. Nasal inflammation in nose-shedders and correlation bacterial density and shedding.<br>Heat maps showing th Figure 5. Nasal inflammation<br>Heat maps showing the media<br>the nasal wash samples a) nos<br>infected group (n = 46) at D2,<br>followed by Benjamini-Hochbe ון<br>וו' tif Figure 5. Nasal inflammation in nose-shedders and correlation bacterial density and shedding.<br>Heat maps showing the median log<sub>2</sub> fold change (FC) in the levels of 29 cytokines and chemokines in the nasal wash samples **a**) nose-shedders (n=28) and **b**) cough-shedders (n=8) compared to non-viral<br>infected group (n = 46) at D2, D6, D16 and D22 post challenge. Used two-tailed Mann-Whitey test,<br>followed by Benjamini-H the nasal wash samples a) nose-shedders (n=28) and b) cough-shedders (n=0) compared to non-viral<br>infected group (n = 46) at D2, D6, D16 and D22 post challenge. Used two-tailed Mann-Whitey test,<br>followed by Benjamini-Hochb followed by Benjamini-Hochberg correction for multiple testing. **C-D)** Correlograms of nose-shedders at D2 and D6 post-challenge, respectively. Spearman rank order correlation values (R) are shown from red (-1.0) to blue followed by Benjamini-Hochberg correction for multiple testing. C-D) correlogiants of nose-shedders<br>at D2 and D6 post-challenge, respectively. Spearman rank order correlation values (R) are shown<br>from red (-1.0) to blue ( at D2 and D1 post-channingly. Depends on the rank of correlation values (R) are shown rated from red (-1.0) to blue (1.0); R values are indicated by colour and square size. P values are indicated by red asterisks. \*p < 0. from Feb (-1.0) to blue (1.0), R values are indicated by colour and square size. P with the indicated by red asterisks. \*  $p < 0.05$ , \* \*  $p < 0.01$ , \* \* \*  $p < 0.001$ . by red asteriska.  $\frac{1}{p}$  as  $\frac{1}{p}$  ,  $\frac{1}{p}$ 



**Figure 1**



Growth Factors

Chemokines

Adaptive

Anti-

Pro-inflammatory











**Figure 5**



## **Figure 6**